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ABSTRACT
Although many workers have demonstrated that the rash of dermatitis herpetiformis 
responds to withdrawal of gluten from the diet, there are many who remain sceptical. 
The role of a gluten free diet in the management of patients with dermatitis herpetiformis 
was re-examined and its beneficial effects confirmed. Furthermore, a gluten free diet 
was shown to protect patients with dermatitis herpetiformis from developing lymphoma 
but the diet had to be strict and the protective effect only became apparent once the diet 
had been adhered to for five years.
Relatives of three patients (with a family history of dermatitis herpetiformis/coeliac 
disease) were screened in order to detect the clinical carrier rate for the genes for 
dermatitis herpetiformis and coeliac disease within these families. The carrier rate in the 
three families studied varied from 23% to 57%. This study demonstrated that many so- 
called “unaffected” relatives of patients with dermatitis herpetiformis may have silent or 
latent coeliac disease. Screening by means of serology alone was shown to be 
unreliable.
The pathogenic mechanisms leading to the development of the rash and enteropathy 
are poorly understood. An infiltrate of T cells, composed mainly of activated CD4 
positive memory cells, was shown to be present in the dermis of dermatitis herpetiformis 
lesional skin. Moreover, these T cells demonstrated over-representation of specific TCR 
V(3 subsets, namely Vp2, V(35.2/5.3 and Vp5.3. These findings would indicate that these T 
cells recognise a specific, but as yet unknown, antigen; the antigen is uniikeiy to be giuten 
because intradermal injection of Frazer’s fraction III failed to elicit the rash of dermatitis 
herpetiformis in patients.
An infiltrate of T cells is also found in the small intestinal mucosa of patients with 
dermatitis herpetiformis and coeliac disease. It has been proposed that these T cells 
belong predominantly to the TH1 group of cells and it has been suggested that IFN-y, 
which is produced by these cells, plays a key role in the production of the small intestinal 
pathology. However, this hypothesis has not been supported by others. Reverse 
transcriptase-polymerase chain reaction and immunostaining demonstrated no statistically 
significant differences in the detection of mRNA for IFN-y and IL-2 or their proteins when 
biopsies from patients with dermatitis herpetiformis who had villous atrophy were 
compared with a control group of patients.
Finally, possible mechanisms, whereby ingestion of gluten in susceptible individuals 
leads to the rash of dermatitis herpetiformis, are discussed.
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CHAPTER ONE 
INTRODUCTION
1.1 HISTORICAL PERSPECTIVE
The term "dermatitis herpetiformis" was first proposed by Dühring in 1884 [Dühring, 1884], 
He used this name for a group of skin diseases which had, up until that juncture, either 
been considered to be unusual variants of "eczema, herpes, or pemphigus" or, in some 
cases as undescribed diseases. In fact, Dühring first recognised the condition as early as 
1871, but it was only by observing additional cases that he became confident enough to 
suggest that these diseases, despite the fact that some cases were dissimilar, were 
indeed the same disease. Dühring included Hebra's "impetigo herpetiformis" [Hebra, 
1872], which we recognise today as pustular psoriasis, under his classification of 
dermatitis herpetiformis .
Dühring found that the disease was rare. All of his patients, with one exception, were 
adults, including both sexes in about equal proportion. He stated that the disease was 
chronic and characterised by exacerbations or relapses. Most cases persisted for years. 
He found that all body sites could be affected, including both flexor and extensor surfaces, 
face, scalp, elbows, knees, palms and soles.
The disease was summarised by Dühring as follows:
1. The existence of a distinct, well-defined, rare, serious, inflammatory disease of the 
skin, manifestly of an herpetic nature, characterised by systemic disturbance, a great 
variety of primary lesions, by severe itching and burning, and by a disposition to appear in
15
repeated successive outbreaks.
2. That the disease is capable of exhibiting itself in many forms, all having a tendency 
to run into or to succeed one another irregularly in the natural course of the process.
3. The principal varieties are the erythematous, papular, vesicular, bullous and 
pustular, which may occur singly or in various combinations.
4. That it is a remarkably protean disease.
5. That the pustular variety is the same manifestation as the disease described by 
Hebra under the name "impetigo herpetiformis", this being the only form hitherto 
described.
6. That the several other and equally important forms are worthy of special remark.
7. That the term "dermatitis herpetiformis" is sufficiently comprehensive and 
appropriate to include all varieties of the process.
8. That it may occur in both sexes, and in women independent of pregnancy.
9. That it usually pursues a chronic, variable course, often lasting years, and is 
exceedingly rebellious to treatment.
In 1888, Brocq published his rather lengthy report on the history of bullous diseases and
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commented on Dühring's newly described DH [Brocq, 1888]. Brocq, however, was of the 
opinion that impetigo herpetiformis should not be classified with DH:
"Que l'impétigo herpétiformis d'Hebra nous paraît constituer une entité morbide à part, et
that the small intestinal changes could be secondary to gluten intolerance [Fry et ai, 1967] 
and this was confirmed a year later [Fry et al, 1968]. It was also suggested in 1968 that the
17
ne saurait, d'après nous, rentrer dans la dermatite herpétiforme de Dühring."
Following Dühring's description In 1884, DH was lumped together with bullous 
pemphigoid and pemphigus. There was much confusion and debate with regard to the 
separation of these diseases. Auspitz had already described intraepithélial separation in 
pemphigus in 1881, which he called acanthoiysis, but this was forgotten and had to be 
"rediscovered" [Auspitz, 1881]. Civatte redescribed acanthoiysis and in 1943 he 
demonstrated that pemphigus could be differentiated histologically from DH and erythema 
multiforme (EM) - he demonstrated the intra-epidermal nature of the blister in pemphigus 
and the sub-epidermal nature of the blister in DH and EM [Civatte, 1943]. He emphasised 
the importance of biopsying blistering rashes to differentiate pemphigus from the sub- 
epidermal blistering lesions. This was again emphasised in Lever's histopathological study 
of pemphigus published in 1951 [Lever, 1951].
The next important milestone came in 1966 when Marks and Shuster demonstrated the 
presence of enteropathy similar to that found in idiopathic steatorrhoea in nine out of 
twelve DH patients [Marks et ai, 1966]. A high prevalence of similar small intestinal 
changes in DH patients was again reported by van Tongeren et ai in 1967 [van Tongeren 
et al, 1967] and later in the same year by Fry et al [Fry et al, 1967]. Fry also suggested
t
Ji;-
skin lesions were gluten dependent [Fry et al, 1968] although this suggestion was rejected 
by others [Shuster et si, 1968; Weinstein et ai, 1971]. Later studies confirmed Fry's original 
suggestion that the rash Is Indeed gluten dependent [Fry et al, 1973; Heading et al, 1976; 
Harrington & Read, 1977; Reunala et al, 1977; Katz et al, 1980; Frôdin et al, 1981; 
Ljunghall & TJernIund, 1983; Gawkrodger et al, 1984].
The late 1960s saw the advent of immunofluorescence, pioneered by Cormane. He was 
able to demonstrate the presence of immunoglobulin at the dermo-epidermal junction in 
patients with DH [Cormane, 1967]. This finding was Investigated further by van der Meer 
who found that this Immunoglobulin was in fact immunoglobulin A (IgA) which formed a 
"striking and consistent granular pattern" at the dermo-epidermal junction [van der Meer, 
1969]. Later It was recognised that there were two patterns of IgA deposition: granular 
deposits in the tips of the dermal papillae and a linear pattern along the dermo-epidermal 
junction. More recently, the linear pattern has been subdivided into linear granular and 
linear homogeneous. The linear granular pattern is seen in DH but the linear 
homogeneous pattern has been recognised to be pathognomonic for a further 
immunobullous disorder which Is now known as linear IgA disease. The presence of 
granular deposits of IgA within the dermal papillae or along the dermo-epidermal junction 
is now recognised as a pre-requisite for the diagnosis of DH.
1.2 CLINICAL OVERVIEW
1.2.1 Introduction
DH is an uncommon immunobullous disorder characterised by a chronic, symmetrical 
eruption consisting of urticated lesions, papules and blisters which typically occur on the 
extensor aspects of the limbs and dorsal aspect of the trunk, particularly over the scapulae
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(Figure 1.1). Severe and persistent itch is a dominant feature. Its onset may occur at any 
age but it usually presents during the third decade. In adults, it is slightly more common in 
males with a male:female ratio of 3:2 compared with a maleifemale ratio of 1:2 in children 
[Ermacora etal, 1986].
1.2.2 Prevalence and geographical distribution
Few studies have looked at the prevalence of DH. Those which have been performed 
suggest that in Britain it occurs in approximately 12 per 100 000 population [Gawkrodger 
et al, 1984] which is similar to the prevalence found in Finland [Reunala & Lokki, 1978] but 
lower than that found in Sweden [Christensen et al, 1973; Mobacken et al, 1984]. There 
have been even fewer studies which have looked at the geographical distribution of DH; it 
shares the same geographical distribution as CD and so it is found in European countries 
and those countries to which Europeans have emigrated.
1.2.3 Direct Immunofluorescence of skin
The clinical diagnosis of DH is confirmed by biopsying un involved skin to detect the 
presence of IgA. The majority of patients with DH have granular deposits of IgA within the 
dermal papillae; approximately 10% of patients have a linear granuiar pattern along the 
dermo-epidermal junction (Figure 1.2). The igA is deposited throughout the skin but it is 
important that the biopsy for direct immunofluorescence is obtained from uninvolved skin 
as the IgA may be destroyed in peritesional skin by the inflammatory process thus 
resulting in a falsely negative result.
19
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FIGURE 1.1: Dermatitis herpetiformis lesions on
(a) the extensor aspect of the elbows
(b) the extensor aspect of the knees
FIGURE 1.2: Direct Immunofluorescence of dermatitis herpetiformis skin
demonstrating
(a) Granular deposits of IgA within the dermal papillae
(b ) Linear granular deposition of IgA along the dermo-epidermal junction
1.2.4 Histology
Biopsy of iesionai skin in DH demonstrates the presence of subepidermal blistering, 
microabscesses containing neutrophils In the adjacent dermal papillae and a perivascular 
infiltrate of mononuclear cells in the dermis (Figure 1.3). It is not necessary to perform a 
lesional biopsy to confirm the diagnosis as this is achieved by performing direct IF; indeed, 
histology cannot reliably differentiate between DH and two other immunobullous disorders, 
linear IgA disease and bullous pemphigoid [Blenkinsopp et al, 1983].
1.2.5 Gluten sensitive enteropathy and malabsorption
As already mentioned in the historical section, DH is associated with gluten sensitive 
enteropathy and it is likely that all patients have intestinal involvement Two thirds of 
patients with DH have abnormal small intestinal mucosal architecture following a single 
small intestinal biopsy [Marks at ai, 1966; Fry et ai, 1967] but 95% of patients can be 
shown to have architectural changes following multiple biopsies [Brow et al, 1971]. Thus, 
the mucosal changes may be patchy. However, even in patients with normal mucosal 
architecture, there is evidence of gluten sensitive enteropathy as demonstrated by the 
presence of raised intra-epithelial lymphocyte counts [Fry et al, 1974] and induction of 
architectural change following gluten challenge [Weinstein et al, 1971]. More recently, it 
has been shown that all patients with DH have raised numbers of intra-epitheliai cells 
bearing the y/ô T cell receptor [Savilahti et al, 1992].
The morphological changes of the small intestine in DH are indistinguishable from those 
seen in coeliac disease. It is now recognised that there is a spectrum of changes and 
these can be broadiy categorised into the following groups [Marsh, 1992]:
1. infiltrative lesions
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2. hyperplastic lesions
3. destructive (flat) lesions
Infiltrative lesions are characterised by:
• normal mucosal architecture
• infiltrate of lymphocytes in epithelium
Hyperplastic lesions are characterised by:
• normal villi
• enlarged crypts
• infiltrate of lymphocytes in the epithelium
Destructive (flat) lesions are characterised by:
• flat surface epithelium
• hypertrophic crypts
• infiltrate of lymphocytes in the epithelium
• lamina propria sweliing
In addition to the changes listed above, as the severity of mucosal damage progresses, 
the columnar epithelial cells with their well developed brush border become progressively 
more cuboidal with attenuation of their brush borders. Increased cellularity of the lamina 
propria occurs and the infiltrate is composed mainly of lymphocytes and plasma cells.
The majority of the cells found in the epithelium, as in the normal intestine, are T 
lymphocytes of the CD8+ (suppressor/cytotoxic) subset. This is in contrast with the lamina
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propria where most of the cells are T lymphocytes of the CD4+ (helper) subset.
All mucosal changes are reversible following withdrawal of gluten from the diet with the 
exception of the raised number of lymphocytes bearing the y/5 T cell receptor.
Most patients with DH have no gastrointestinal symptoms. Less than 10% have 
symptoms of gluten sensitive enteropathy including bloating, diarrhoea and malabsorption 
[Fry et al, 1967; Fraser et al, 1967; Shuster et al, 1968; Brow et al, 1971]. Although most 
DH patients are asymptomatic, laboratory studies documenting abnormal intestinal 
function have been reported including abnormal D-xylose, iron, folate, glucose, water and 
bicarbonate absorption [Fry et al, 1967; Fraser et al, 1967; Shuster et al, 1968; Brow et al, 
1971].
Thus, although the majority of DH patients have changes of their small intestinal mucosa 
in keeping with gluten sensitive enteropathy, these changes tend to be milder than those 
observed in coeliac disease. Consequently, only a minority of DH patients have gastro­
intestinal symptoms and significant malabsorption. Gluten intolerance in patients with DH 
is manifested by the development of the rash.
1.2.6 HLA associations
The discovery that patients with DH had GSE led several investigators to initiate studies to 
determine if the HLA associations present in patients with isolated GSE were also present 
in patients with DH. Initial studies revealed that 58% of DH patients expressed the HLA 
class I antigen B8 compared with 20-30% of controls [Katz et al, 1972; White et al, 1973]. 
However, when only patients with granular deposits of IgA were studied, It was found that
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compared with 40% of controls [Solheim et al, 1976; Thomsen et al, 1976; Strober, 1980;
The HLA associations for DH and GSE are essentially similar. However, not all 
individuals expressing these genes develop DH or GSE and so other factors such as 
additional genes and environmental factors must be operating to contribute towards the 
development of these disorders.
1.2.7 Autoimmune disease associations
Patients with DH are at risk of developing autoimmune diseases. The commonest 
autoimmune disease to occur In association with DH is thyroid disease. Thyroid antibodies 
were shown to be present in 48% of patients with DH [Weetman et al, 1988] with overt
25
70-90% expressed HLA B8 [Karpati et al, 1986; Sachs et al, 1986; Sachs et al, 1988; Hall 
et al, 1989].
Further investigations revealed stronger associations with the HLA class II antigens, 
HLA-DR3 and HLA-DQw2: 90-95% of patients with DH were found to express HLA-DR3
compared with 23% of normal controls; 95-100% were found to express HLA-DQw2
a
Park etal, 1983; Sachs etal, 1986; Hall etal, 1989].
Molecular analysis of the HLA-DR and HLA-DQ genes has shown the strongest 
association of DH is with the HLA-DQ alleles DQ B1*0201 and DO A1*0501 in c/s or trans 
position (DQ2): almost 90% of DH patients carry the genes encoding this heterodimer 
whilst most of the remainder carry the genes for the heterodimer DQ A1*03 81*0302 
(DQ8) [Fronek etal, 1991; Otiey etal, 1991; Spurkland A etal, 1997].
thyroid disease occurring In 5-34% [Davies et al, 1978; Gawkrodger et al, 1984; 
Cunningham etal, 1985; Weetman etal, 1988].
The next most frequent autoimmune disease to occur in patients with DH is pernicious 
anaemia. As many as 30% of a cohort of DH patients were found to have gastric parietal 
cell antibodies with 3% having pernicious anaemia [Fry, 1992]. This incidence of 
pernicious anaemia was similar to another study [Gawkrodger et al, 1984].
DH patients are also at risk of developing diabetes mellitus [Holt et al, 1980]. Eight (4%) 
patients out of a cohort of 212 patients attending St Mary’s Hospital dedicated DH clinic 
had diabetes mellitus [unpublished observations].
Other autoimmune diseases which have been reported to occur in association with DH 
include rheumatoid arthritis, lupus erythematosus, primary biliary cirrhosis, autoimmune 
chronic active hepatitis and vitiligo [Kaplan etal, 1992].
1.2.8 Lymphoma
Patients with DH, like patients with CD, are at risk of developing lymphoma and these 
lymphomas can be intestinal or extra-intestinal [Andersson et al, 1971; Mânsson, 1971; 
Goodwin & Fry, 1973; Tonder etal, 1976; Silk etal, 1977; Gould & Howell, 1977; Freeman 
et al, 1977; Leonard et al, 1983]. A previous retrospective study of 109 DH patients 
reported that DH patients taking a normal diet appeared to have a greater risk of 
developing lymphoma than those adhering to a GFD although the results were not 
statistically significant [Leonard et al, 1983].
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Figure 1.3: Histology of DH skin demonstrating subepidermal blistering, 
collections of neutrophils within and just below the sudepidermal blister and a 
perivascular infiltrate of mononuclear cells in the dermis (x100).
1.2.9 Treatment
DH can be treated with drugs (dapsone, sulphamethoxypyrldazine or sulphapyridlne) or 
with a GFD or with a combination of drugs and GFD.
Today, two sulphonamides, sulphamethoxypyrldazine and sulphapyridlne, are used to 
treat DH. Sulphapyridlne was the first drug used to treat DH successfully [Costello, 1940]. 
It was one of the first antibiotics available and was given to patients with DH because it 
was believed that their rash was an allergic manifestation to a bacterial infection. 
Sulphonamides have many adverse effects including nausea, lethargy, depression, 
rashes, hepatitis and bone marrow suppression; pneumonitis has been described with 
sulphamethoxypyrldazine [McFadden etal, 1989].
Dapsone, which is a sulphone, was first used in 1950 and is extremely effective in 
controlling the skin lesions of DH [Esteves and Brandao, 1950]. Indeed, prior to the advent 
of immunofluorescence, a trial of treatment with dapsone was used as a diagnostic test. 
Dapsone has many adverse effects which are common and include headache, lethargy 
and depression. Patients taking dapsone will develop some evidence of haemolysis, the 
degree of which can be monitored by measuring the reticulocyte count. Severe haemolytic 
anaemia may occur as an idiosyncratic response or in patients with glucose-6-phosphate 
dehydrogenase deficiency and this deficiency must be checked for in at-risk patients 
before commencing dapsone.
All patients taking lOOmg of dapsone daily will have some degree of 
methaemoglobinaemia and sulphaemoglobinaemia. Peak methaemoglobin concentrations 
occur by the second week of treatment, and can exacerbate ischaemic heart disease in
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susceptible individuals. Other occasional adverse effects include hepatitis, agranulocytosis 
and neuropathy which may be sensory, motor or both. Neuropathy can occur at any stage 
after commencing dapsone and is usually reversible.
The mechanism whereby dapsone and the sulphonamides exert their effect is unknown. 
It has been shown that they can prevent migration of neutrophils to extravascular sites by 
interfering with adhesion molecules, the leukocyte integrins [Booth etal, 1992]. It is likely 
that additional, hitherto unidentified, properties also play a role.
Neither dapsone nor the sulphonamides have any effect on the enteropathy of DH. Both 
the rash and the enteropathy of DH respond to withdrawal of gluten from the diet and this 
shouid be the treatment of choice. Patients who adhere to a strict GFD should achieve 
complete control of their rash just over two years after commencing the diet. Until control 
of the rash has been achieved by the diet, dapsone or one of the sulphonamides will be 
required in addition. Patients who adhere to their diet strictly should be able to start 
reducing their medication after approximately 6 months [Fry et al, 1973]. The less strict the 
diet, then the longer will be the period until complete control is achieved.
Although several studies have confirmed the efficacy of a GFD in treating the rash of 
DH, this is not universally accepted by dermatologists and gastroenterologists. 
Consequently, there are many dermatologists who fail to advocate the use of a GFD in the 
treatment of these patients.
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1.3 Aims of study
In general terms, the work of this thesis aimed to improve the management of patients 
with DH; to assess the incidence of clinical expression of the gene for CD and DH within 
families; and to elucidate the pathogenic mechanisms involved in the development of the 
skin and small intestinal lesions.
The specific aims were:
1. To re-evaluate the efficacy of a GFD in the treatment of DH and to assess the long 
term benefits of the diet, particularly with respect to the development of lymphoma.
2. To study so called "unaffected" members of families with more than one member 
with CD or DH in order to determine the incidence of those expressing the gene(s) 
for CD/DH within these families.
3. To determine whether the skin lesions of DH are due to T cell mediated responses 
to antigen.
4. To determine whether intestinal T cells in DH patients belong to the TH1 or TH2 
sub-groups of T cells.
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CHAPTER TWO 
CLINICAL ASPECTS
1. GLUTEN-FREE DIET IN THE MANAGEMENT OF PATIENT WITH 
DERMATITIS HERPETIFORMIS
2.1.1 Introduction
It has always been controversial as to whether the rash of DH truly responds to withdrawal 
of gluten from the diet. Van Tongeren [Van Tongeren et al, 1967] reported a patient with 
DH whose rash Improved when he was treated with a gluten free diet (GFD) but worsened 
when gluten was re-introduced into the diet. Fry et a! [1968] proposed that the rash of DH 
was dependent on the presence of gluten In the diet and later reported clearance of the 
rash In three out of seven patients who had been taking a GFD for one year [Fry et al, 
1969]. Some early investigators were unable to confirm that the DH rash was gluten 
dependent but their findings were based on studies in which the GFD was given to the 
patients for short periods of time [Shuster et al, 1968; Weinstein et al, 1971]. Subsequent 
Investigators were able to confirm that the rash of DH was Indeed dependent on the 
presence of gluten In the diet [Fry et al, 1973; Heading et al, 1976; Harrington & Read, 
1977; Reunala et al, 1977; Frôdin et al, 1981; Fry et al, 1982; Ljunghall and Tjerniund, 
1983; Gawkrodger et al, 1984]. Of these latter studies, the largest was performed by 
Reunala and his colleagues [Reunala et al, 1977]: they were able to show that 23 out of 81 
patients taking a GFD for 6 - 3 6  months were able to discontinue their medication 
completely a mean of 24 months after commencing the GFD. Fry reported similar findings 
in 1982: of 42 patients taking a GFD, 30 were eventually able to discontinue their 
medication after a mean of 29 months after commencing the diet [Fry etal, 1982].
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Despite the published literature supporting the benefits of a GFD in treating DH patients, 
there continue to be many dermatologists and gastroenterologists who remain sceptical.
Therefore, I performed this retrospective study of a large cohort of DH patients to confirm 
finally the overwhelming benefits of a GFD in the treatment of the rash of DH.
'■ f
2.1.2 Methods
Patients
Two hundred and twelve patients (128 male, 84 female; average age at presentation 42 
years, range 9-83 years) with DH were seen in the dedicated clinic at St Mary's Hospital
The casesheet for each patient was available for me to see and to extract the relevant 
Information. The diagnosis In all cases had been confirmed by demonstration of IgA 
deposits In the upper dermis. Treatment with a GFD had been discussed with all patients.
Classification of strictness of GFD
I discussed the strictness of each patient’s diet with the consultants in charge of the
during the period 1967-92. Many of the patients had been followed up by a single 
physician since 1967 (Professor Lionel Fry). The number of patients attending this clinic 
had steadily grown since its inception. The casesheets for these patients had always been 
kept in the Dermatology Department: meticulous notes had been made of the clinical signs 
and symptoms; results of investigations; treatment modalities including drug doses; 
response of the rash to withdrawal of gluten from the diet. A dietitian had always been in 
attendance at the clinic and had also recorded dietary strictness in the patients’ 
casesheets. The DH patients in this study had all been under the care of Professor Lionel 
Fry and/or Dr Jonathan Leonard.
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Group ! strict - when patients could not be faulted
Group II partial with occasional lapses - when patients deviated more than
twice per year
Group III partial with frequent lapses - when patients deviated more than
twice per year, but no more than once per week.
Patients whose dietary lapses occurred more than once per week were considered to be 
taking a normal diet.
Small intestinal biopsy
When possible, patients underwent a small intestinal biopsy prior to commencing their 
GFD.
Skin biopsies
Skin biopsies, to detect the presence of IgA in patients whose rash was controlled by GFD 
alone, were repeated at intervals.
Time to reduce and stop medication after commencing a GFD
The time taken to reduce and eventually stop the sulphones or sulphonamides, required to 
suppress the rash of DH, was calculated In patients who were successful in controlling
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patients (Professor Lionel Fry and Dr Jonathan Leonard) and with the DH clinic's dietitian 
(Samantha Sargant). Following these discussions, I classified patients who were taking a 
GFD into the following categories listed below.
their rash by diet alone.
Statistics
The Mann-Whitney U-test was applied to determine significant differences in the times 
taken to reduce and stop medication between groups i, II and III.
2.1.3 Results
Dietary status
An analysis of patients according to diet is shown in Table 2.1, The GFD was tried by 172 
(81%) of the patients, of whom 133 (63%) continued to take the diet. Seventy-eight of the 
patients taking a GFD achieved control of their rash by diet alone, and 55 continued to 
require medication in addition to their GFD for complete control. Sixty-nine patients opted 
to continue with a normal diet and medication; an additional 10 patients entered remission, 
i.e. they were taking a normal diet and required no medication.
Reasons for patients not taking or discontinuing GFD
Of the 79 patients taking a normal diet, 39 had tried a GFD and then stopped it. Patients 
who tried the diet and then discontinued it did so for the following reasons: (i) they found 
that the diet interfered with their family life; (ii) it was socially limiting; (ill) their work made it 
difficult to adhere to the diet; (iv) some found the diet was too difficult to adhere to, and 
these patients were usually poorly motivated; (v) two entered spontaneous remission. The 
reasons for the 40 patients not taking a GFD were: (i) they simply did not wish to try this 
treatment; (ii) they considered it would restrict their social life; (ill) they thought it would 
interfere with their work, e.g. patients who had to travel a great deal.
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Spontaneous remission of skin lesions
Of the 77 patients taking a normal diet, eight entered spontaneous remission, giving a 
remission rate of 10%. These patients retained IgA in their skin, but were able to take a 
normal diet without recurrence of skin lesions. A further two patients went into remission; 
one of these had been taking a strict GFD, and remission was discovered fortuitously 
when his rash did not recur whilst he was participating in a gluten challenge study 
[Leonard et al, 1983]. The remission rate in patients taking a strict GFD is unknown, as 
this could only be determined by stopping their diet. The remaining patient whose disease 
remitted had been taking a partial GFD. He was the only patient not taking a strict GFD 
who lost the IgA from his skin, and this was demonstrated in two separate biopsies.
Strictness of diet
Of the 133 patients taking a GFD, 44 (33%) were thought to be strictly adhering to the diet 
(group I), and could not be faulted by the dietitian. Of the remaining 89 patients, 22 were 
taking a GFD with occasional lapses (group II), 62 were taking a GFD with frequent lapses 
(group III), and in five the strictness of the diet was unknown (Table 2.2).
Small intestinal pathology at presentation
Small intestinal biopsies were performed in 166 patients at presentation and prior to 
starting a GFD. One hundred and sixteen (70%) of these patients had villous atrophy, 65 
(39%) had partial villous atrophy, and 51 (31%) total villous atrophy. In the group whose 
disease was controlled by strict GFD alone (group I), 10 of 35 (29%) patients had a normal 
villous architecture of their small intestinal biopsy prior to commencing a GFD (biopsies not 
performed in six.)
36
Loss of IgA from the skin
Loss of IgA from the skin was observed In 10 of 41 (24%) patients taking a strict GFD. The 
average time after commencing a GFD until loss of IgA was detected was 13 years (range 
5 - 2 4  years); the average duration of control of the rash by GFD alone until loss of IgA 
was 10 years (range 3 - 1 6  years). Of the remaining patients taking a strict GFD, a 
reduction in the amount of IgA in the skin was observed in 11.
i
Time taken to reduce and stop medication after commencing GFD
The results are shown in Table 2. 3.
$
Patients who were taking a strict GFD (group I), and who were eventually able to 
discontinue medication, reduced their medication by 50% after a mean of 13 months, and 
were able to discontinue medication after a mean of 28 months from commencement of 
the diet. Patients who erred from the diet no more than twice per year (group II), and who 
were eventually able to discontinue medication, reduced their medication by 50% after a 
mean of 14 months, and were able to stop their medication a mean of 44 months from 
commencement of the diet. Patients who frequently strayed from the diet (group III), but 
who were eventually successful in stopping medication, took a mean of 21 months to 
reduce medication by 50%, and 62 months to stop medication from the time of 
commencement of the diet. The time taken to discontinue medication in those who 
adhered strictly to their GFD (group I) was significantly shorter than in those who strayed 
frequently from their diet (group III) (P < 0.02, Mann-Whitney U test). The differences 
between groups I and II, and also between groups II and III, were in line with the general 
trend that the stricter the GFD the less time was required to cease medication, although 
these differences failed to reach statistical significance.
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2.1.4 Discussion
This large series of patients confirms the observation that the rash of DH is gluten- 
dependent, and that it takes many months for total resolution to occur. Treatment with a 
GFD abrogates the need for medication associated with a high frequency of side-effects 
[McFadden et al, 1989], Patients who adhere strictly to their diets should be able to start 
reducing the dose of their medication a few months after commencing the diet and stop 
approximately after 28 months. The less strict the diet, the longer it takes before patients 
can reduce and discontinue their drugs. Indeed, some patients who continue to have small 
amounts of gluten in their diet may not be able to stop their medication completely. Other 
advantages of a GFD are that patients often experience a feeling of well-being after 
commencing the diet, and malabsorption is corrected due to resolution of the enteropathy. 
The disadvantages of the diet are that it is difficult to adhere to, and patients must be 
motivated, gluten-free products are expensive (although many are available on 
prescription In the U.K.) and many patients may find that the diet interferes with family life, 
work or social activities. Thus although a GFD is the treatment of choice, there will be 
patients for whom the diet is not suitable. Once committed to a GFD this treatment will be 
lifelong as remission is uncommon.
Three patients who had been taking a "strict" GFD were unable to stop their medication. 
One was thought to have been taking his strict GFD for 4 years, but was unable to reduce 
the dose of his medication. Of the other two patients, one had been taking a strict GFD for 
4 years and was successful in reducing her daily dapsone requirements by over a half. 
The third patient was an insulin-dependent diabetic who was diagnosed as having coeliac 
disease in childhood and had been taking a GFD since then. These patients were taking 
GFDs when they presented to the DH clinic, and their small intestinal biopsies were
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normal, confirming that they were adhering to their diets. It is known that a GFD containing 
proprietary "gluten-free" products is not completely devoid of gluten [Ciclitira et al, 1984], 
and perhaps there was a sufficient amount of gluten present in these patients' diets to 
trigger their skin lesions.
A further four patients had been diagnosed as having coeliac disease in childhood.
Patients who had been diagnosed as having coeliac disease in childhood, and who had 
been taking a strict GFD, should not develop the skin lesions of DH later in life. These four 
patients were not taking a GFD when they presented to the DH clinic, and villous atrophy
■■■
was present on their small intestinal biopsies.
The incidence of spontaneous remission of the rash in patients taking a normal diet in 
this study is similar to that reported in other series [Alexander et al, 1975]. The reason for 
remission is unknown. There is evidence to suggest that T cells may be implicated in the 
pathogenesis of the skin lesions in DH, although the antigen-specificity of these T cells has 
not been identified [Nestor et al, 1987]. However, it is likely that the antigen is a 
component of the skin. The development of anergy of these T cells is one possible 
mechanism whereby remission could occur.
I
It is thought that the presence of IgA in the skin is necessary for the production of skin 
lesions, but it is equally possible that it is an epiphenomenon. It has been suggested that 
neutrophils, which are a characteristic feature of DH lesions, bind to the IgA, with 
subsequent activation and release of enzymes [Graeber et al, 1993]. In the cohort of 
patients studied here, 10 of 41 (24%) patients taking a strict GFD lost the IgA from their 
skin after periods ranging from 3 to 16 years following complete control of the rash by diet
began, and 80 when he achieved remission. At the time of writing, he was taking a normal 
diet. It is possible that the loss of IgA from this patient's skin was related to his age, DH 
tends to be less severe in elderly patients, and this may be a result of altered immune 
function in the elderly.
in conclusion, a GFD is the most appropriate treatment for patients with DH. The 
success of a GFD in the management of patients with DH is aided by the contribution of a 
dietitian who has a special interest in coeliac disease. In addition to reducing the need for 
drugs with a high incidence of side effects, treatment with a GFD produces resolution of
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alone. It is difficult to ascertain with accuracy how quickly the IgA was lost in these 
patients. In an earlier report, IgA was present in patients whose rash had been controlled 
by a GFD for periods ranging from 6 months to 7 years [Fry et al, 1978]. In a subsequent 
study, three patients who had been taking a GFD for a minimum of 7 years were found to 
have lost the IgA from their skin [Leonard et al, 1983]. This same study demonstrated 
recurrence of the IgA and the rash following gluten challenge [Leonard et al, 1983]. It is 
thought that the IgA in the skin originates from the small intestine, because of the 
presence of "J" chains in the skin [Unsworth et al, 1982]. The stimulus for IgA production 
and its subsequent deposition In the skin is likely to be gluten. It might therefore be asked 
why it takes so long for the IgA to disappear from the skin. It has been demonstrated that 
IgA is difficult to elute from the skin [Egelrud et al, 1985; Meyer et al, 1987], indicating that 
it is tightly bound, and this may explain why it may take many years for the IgA to gradually 
disappear.
Loss of IgA was observed in a single patient who was not taking a strict GFD. This 
patient was one of the oldest to attend the DH clinic. He was 69 years old when his rash
the associated enteropathy and prevents malabsorption.
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TABLE 2.1 : Analysis of patients according to diet
DIETARY STATUS NUMBER OF PATIENTS
GFD alone
GFD and medication
Normal diet and medication
Remission (normal diet, no medication)
78
55
69
10
TOTAL 212
TABLE 2.2: Analysis of patients according to strictness of gluten free diet
err no more than twice per year
err more than twice per year, but no more than once per week
Strictness of diet Diet alone Diet & medication
strict (group 1) 41 3
Partial GFD (group I!)* 9 13
Partial GFD (group l l i f 26 36
Strictness unknown 2 3
TOTAL 78 55
TABLE 2.3: Time taken in months to reduce and stop medication from 
commencement of giuten free diet in patients whose rash was controiied by diet 
alone
Strictness of diet
Group 1 
(strict GFD)
Group II 
(partial GFD)"
Group III 
(partial GFD)'
Mean time 
(months) to 
reduce medication 
by 50% ± SEM
13±3  
(range 1 -  66) 
n = 25
14 ±4  
(range 3 -  24) 
n = 5
21 ±6  
(range 6 -  92) 
n = 14
Mean time 
(months) 
to stop medication 
±SEM
28 ± 4** 
(range 4 -  88) 
n = 30
44± 15 
(range 9 -1 0 6 )  
n = 7
62 + 13** 
(range 6 -  223) 
n = 19
'I
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n
SEM
number of patients in analysis (data was not available for all patients) 
standard error of the mean
significant difference at P < 0.02 (Mann-Whitney U-test) between groups I 
and III
err no more than twice per year
err more than twice per year, but no more than once per week
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2, A GLUTEN FREE DIET PROTECTS PATIENTS WITH 
DERMATITIS HERPETIFORMIS FROM DEVELOPING LYMPHOMA
2.2.1 Introduction
It is known that patients with DH, like patients with CD, have an increased risk of 
developing lymphoma when compared with the general population [Reunala et al, 1982; 
Reunala etal, 1983; Leonard etal, 1983; Sigurgeirsson etal, 1984]. It has previously been 
suggested that if patients with CD adhered to a strict GFD for 5 years or longer, then their 
risk of developing lymphoma would be no greater than that of the general population 
provided that they continued to take the diet [Holmes et al, 1989]. Although there have 
been no other detailed studies, anecdotal evidence supports this view [McCarthy et al, 
1990].
A GFD has been used in the management of patients with DH at St. Mary's Hospital, 
Paddington since 1967 and patients have been kept under regular review. The cohort of 
patients attending St Mary’s Hospital was studied in conjunction with a comparable group 
of Finnish patients and the resulting data were analysed with a view to determining 
whether a GFD protects patients with DH from the development of lymphoma.
2.2.2 Methods 
Patients
487 (275M:212F) patients were included in the study; 206 had been followed up in St.
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followed up at Tampere University Hospital, Finland from 1976 until May 1993.
The diagnosis of DH had been confirmed in both the British and Finnish cohorts by the 
demonstration of IgA in the dermal papillae of uninvolved skin. For the purpose of this 
study, the point of entry was taken as being the date of first attendance.
Information was gathered from patients themselves, from casesheets (see section 2.1,2) 
and from the family doctor. Where death had occurred, the date, autopsy result and death 
certificate were obtained for patients seen at St. Mary’s Hospital. Deaths and cancers in 
the Finnish group were checked in the Finnish Health and Cancer Registry for 1993. 
Patients who had defaulted from the clinic in the UK were traced from the National Health 
Service Central Register at Southport. Twenty patients from St Mary's Hospital could not 
be traced and were considered to have been at risk from the point of entry until their last 
outpatient attendance. Data were available on all the Finnish patients. Information 
pertaining to the English patients was collected by Dr Helen Lewis (Dermatology Registrar) 
and myself. The English patients were under the care of Professor Lionel Fry and/or Dr 
Jonathan Leonard. Information on the Finnish patients was collected by Professor Timo 
Reunala -  the majority of these patients had had small intestinal biopsies performed by 
Professor Reunala’s colleague, Dr Peka Collin.
Dietary Groups
Patients were classified into groups depending on the degree of gluten ingestion:
Group I This group included patients who adhered to a strict GFD for five or more
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Mary’s dermatitis herpetiformis clinic from 1969 until May 1993; 281 patients had been
- i»
I
consecutive years. This five year limit was selected prior to analysis of the 
data and was the cut off point chosen in a similar study carried out in 
patients with CD [Holmes et al, 1989].
Group II This group was designated the partial GFD group and included those who
attempted to adhere to a GFD but assessment by a dietitian revealed 
ingestion of gluten, although the degree of ingestion was less than the 
equivalent of 1-2 pieces of bread weekly.
Group III This was the normal diet group. This included those patients who had no
record of taking a GFD, those who had attempted a GFD but dietary 
evaluation revealed only sporadic adherence to GFD, those in whom the 
strictness of gluten exclusion was uncertain and those who had received a 
GFD for less than five years.
Statistical analysis
Statistical analysis was performed by a professional statistician, John Fry. He analysed the 
data using the "man years at risk" llfe-table method [Hill, 1972] where the observed 
number of deaths or cancer registrations is compared with that expected from the general 
population rates. The rates are broken down by sex and 5-year age group. The ratio of the 
observed to the expected number of registrations is described as the standardised 
registration ratio (SRR). Patients commenced on a strict GFD were assumed to contribute 
man years to the normal diet group until 5 years after starting the diet. If the diet was 
discontinued, the patient contributed man years to the GFD group for a further 5 years 
following which they were assigned to the normal diet group.
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Eight (1.6%) patients with DH developed lymphoma (SRR 3810). The mean time from 
entry into the study until diagnosis of iymphoma was 78 (range 2 - 240) months. Clinical
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To examine the significance of the SRRs the observed number of registrations (O) was 
treated as having a Poisson distribution with mean and variance equal to the expected 
number of registrations (E). To test if the Groups I and II were behaving as Group III, the 
expected number of registrations for each of these groups was multiplied by the SRR/100 
for group III to give the estimated number of registrations if Groups I and II behaved as 
Group III (E2). The probability of observing less than or equal to the observed number of 
registrations using E2 as the Poisson parameter was then calculated.
Death rates are based on 5-year death rates made available by the World Health 
Organisation. Registration rates are based on the 1981 figures from the Office of
Population and Censuses survey for England and Wales and for the 1977-1981 figures 
from the Finnish Cancer Registry.
Histopathology Review
Original paraffin sections of 7 out of 8 tumours diagnosed as lymphoma were available. 
David Evans, Professor of Pathology at St Mary’s Hospital, reviewed this material and 
performed immunoperoxidase studies with antibodies to leucocyte common antigen 
(LCA), B cell antigen CD20 (L26) and T ceil antigens CDS and CD45RO (UCHL1).
2.2.3 Results
The cohort was followed up for a total of 4918 man years: for Group I there were 1153.7 
man years; Group II had 389.4 man years; and Group III had 3375.3 man years.
details and classification are given in Table 2.4. This includes a patient from the Finnish 
group (number 4) who underwent resection of a small bowel reticulum cell sarcoma 11 
years before presentation of DH [Reunala et al, 1982]. After a further three years, whilst 
taking a partial GFD, a histiocytic diffuse-type lymphoma involving the ileum, colon and 
stomach was identified at laparotomy.
All lymphomas occurred in Group III and no lymphoma developed in patients who had 
adhered to a strict GFD for 5 years or more. The difference between Group III and Group I 
reached statistical significance (E2=3.084; P=0.0457). No lymphoma developed in Group 
II but there was no statistical difference compared with group III (E2=0.998; P=0.369).
Twenty two malignancies other than lymphoma were identified (Table 2.5). In Group I a 
patient developed carcinoma of the stomach and a second patient developed carcinoma 
of the prostate. In Group II, one patient developed carcinoma of the colon and a further 
patient had carcinoma of the bronchus diagnosed. The remaining patients with malignancy 
were in Group ill. The overall Incidence of malignancy was marginally greater than the 
expected incidence of 14.44 but this difference did not reach statistical significance.
Three patients developed haematological malignancies other than lymphoma. A male 
patient, aged 67, developed acute lymphoblastic leukaemia 2 months prior to diagnosis of 
DH. A female patient had DH confirmed at age of 48 years. Although she gave a history of 
a typical rash from the time myeloma was diagnosed 4 years previously. These patients 
were not included in the analysis as the presentation of malignancy preceded the 
diagnosis of DH. Finally, a male patient, controlled on dapsone and a normal diet following 
a diagnosis of DH aged 69 years, developed myeloma 5 years later. The difference
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between Group I and Group III for all lymphomas and myeloma reached statistical 
significance (E2 3.458; P=0.0365; SRR 3100).
2.2.4 Discussion
This study has confirmed that there is an increased incidence of lymphoma in patients with 
DH. Furthermore, it has demonstrated that patients with DH who adhere to a strict GFD for 
5 years or longer, have no increased risk of developing a lymphoma compared with the 
general population. This finding supports the protective role of a GFD against the 
development of lymphoma. Three lymphomas occurred in patients treated with a GFD, but 
presentation was within 5 years of commencing the diet. An explanation for this may be 
that the relatively short time on the diet was insufficient to reverse the effect of an 
oncogenic stimulus which may have operated for many years. Alternatively, the lymphoma 
may have already developed before introduction of the gluten free diet, and taken some 
years for clinical manifestations to occur. Interestingly, no lymphoma developed In patients 
taking a partial GFD. However, there was no statistical difference in the incidence of 
lymphoma in this group compared with patients taking a normal diet. It is possible that a 
reduction in gluten intake reduces the risk of developing lymphoma, but the number of 
man years contributed by the partial GFD group was small and may not have allowed 
demonstration of such an effect.
A protective role for a GFD against the development of lymphoma In CD has also been 
suggested [Holmes etal, 1989; Collin etal, 1994]. In coeliac disease, the majority of cases 
of lymphomas, originally termed malignant histiocytosis of the intestine, are thought to be 
of T cell origin, and the term "enteropathy associated T-cell Lymphoma" (EATL) is now 
used [Isaacson et al, 1985]. Furthermore, it has been suggested that In some patients
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adult onset coeliac disease may be due to a low grade iymphoma of intra-epithelial 
iymphocytes [Wright et al, 1991]. However, the site of presentation of lymphoma is not 
confined to the intestine [Fowier & Thomas, 1976].
Although the majority of lymphomas reported in dermatitis herpetiformis have been 
classified as histiocytic tumours, the occurrence of Hodgkin's disease and lymphomas of B
cell origin have also been described [Reunala et al, 1982; Sigurgeirsson et al, 1994; 
Fowler & Thomas,1976; Gawkrodger et al, 1982; Buckley et al, 1983; Mânsson, 1971]. 
Interestingly, lymphomas represented in this study were of a mixed nature, in keeping with 
a recent study from Sweden [Sigurgeirsson et al, 1994], and include those of T and B ceil 
lineage, and Hodgkin's disease.
An increased risk for developing carcinomas of the mouth, pharynx, oesophagus and 
small bowel has been shown in coeliac disease [Holmes et al, 1989; Swinson etal, 1983], 
however no increase of these malignancies has been shown in larger follow up series of 
patients with dermatitis herpetiformis [Sigurgeirsson etal, 1994; Swerdlow e tal, 1993], As 
reported here, carcinomas have been reported In patients with dermatitis herpetiformis, 
but the frequency and site of these malignancies is no different to that seen in the general 
population.
i
The aetiology of iymphoma in patients with coeliac disease or dermatitis herpetiformis is 
unknown but several mechanisms may be involved. Both diseases are associated with a 
wide range of autoimmune disorders [Gaspari et al, 1990] and splenic atrophy and it may 
be postulated that an underlying immunological disturbance In the presence of gluten may 
predispose to the development of lymphoma. The increased risk of developing lymphoma
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In the gastrointestinal tract may be due to polyclonal stimulation of lymphocytes by gluten
;|
giving rise to malignant transformation. Such a malignant clone could arise In proliferating 
T or B cells, and it is possible that myeloma, also reported In these cohorts, may have 
arisen by this mechanism. More general theoretical mechanisms include carcinogens 
gaining access through damaged Intestinal mucosa and mucosal detoxifying enzyme 
depletion allowing accumulation of potentially damaging substances.
The majority of patients with dermatitis herpetiformis do not have symptoms from their 
gluten sensitive enteropathy and the eruption can be controlled by drugs. However, It now 
appears that gluten withdrawal Is protective against the development of lymphoma and
.
this Is a further compelling argument for encouraging patients to adhere to a GFD.
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TABLE 2.4: Details and morphological type of lymphoma occurring in patients 
with dermatitis herpetiformis
* Second lymphoma presentation
+ Patients from Finland
NA not available
Null non-B, non-T
LN lymph node
bm bone marrow
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TABLE 2.4
Patient no. Sex Age of 
presentation 
with DH
Diet Age of 
Presentation 
with 
lymphoma
Site of 
lymphoma
Original 
classification 
of lymphoma
Phenotype & 
revised 
classification
1 M 65 normal 78 axillary LN- 
stage IV
centroblastic B cell 
plasmacytoid
2 M 46 normal 46 bm immunoblastic T cell large cell
3 M 54 normal 63 small intestine histiocytic B cell 
plasmacytoid
4 M 47 partial GFD 50* + widespread- 
ileum, colon, stomach
diffuse-type
histiocytic
NA
5 M 28 strict GFD 
for 4 years
37 + colon histiocytic T cell large cell
6 F 35 strict GFD 
for 2 years
42 + inguinal LNs lymphocytic-
diffuse
Bcell
7 F 64 strict GFD 
for 4 years
68 + mesenteric & 
cervical LNs
histiocytic Null
8 M 67 normal 70 cervical LN, 
bm
Hodgkin's mixed cellularity
TABLE 2.5: Comparison of observed and expected numbers of malignancies
Site of 
malignancy
Observed
number
Expected
number
SRR P
bronchus 7 4.834 144.8 NS
stomach 3 1.671 179.5 NS
colon 2 1.410 141.8 NS
prostate 3 1.760 170.5 NS
breast 2 1.946 102.8 NS
skin 1 1.781 56.1 -
rectum 1 1.062 94.2 -
thyroid 1 0.180 555.6 -
pancreas 1 0.746 134.0 -
myeloma 1 0.155 645.1 -
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3. IDENTIFICATION OF CLINICAL CARRIERS FOR THE GENE(S) 
FOR DERMATITIS HERPETIFORMIS AND COELIAC DISEASE 
WITHIN FAMILIES
2.3.1 Introduction
There is compelling evidence which suggests that dermatitis herpetiformis and coeliac 
disease have a genetic basis which is shared. Both conditions are associated with HLA 
DR3 and DQ2 [Yunis, 1992], and in particular with the DQ alleles A1*0501 and 81*0201 
[Sollid et al, 1989; Hall et al, 1991]. In addition, both have been shown to cluster in 
families: one study, performed on a cohort of patients living in Utah, reported that 6.5% of 
DH patients had first degree relatives with DH [Meyer & Zone, 1987] whilst a further study, 
based on Finnish patients, reported that 4.4% of DH patients had affected first degree 
relatives with DH and 6.1% with CD [Reunala, 1996]. Furthermore, there have been 
several reports of DH and CD occurring within monozygotic twins: some twin pairs were 
found to be concordant for DH whilst in other twins, one had DH and the other CD [Jepsen 
& Oilman, 1980; Kosnai et al, 1985; Green et al, 1986; Anstey et al, 1991; Reunala et al, 
1991]. Thus, genetic factors appear to be important in the aetiology of DH and CD.
It is also known that patients diagnosed as having coeliac disease only represent the tip 
of the iceberg as those with milder forms are likely to remain undiagnosed as they are 
either asymptomatic or have non-specific or atypical symptoms. Serological screening of 
population groups has highlighted this fact [Catassi et al, 1994; Unsworth & Brown, 1994]. 
Consequently, it is possible that previous studies may have underestimated the
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occurrence of CD within relatives of patients with DH, as only those with overt disease 
would have been identified. Two previous studies have demonstrated that if relatives of 
patients with DH have small intestinal biopsies, then as many as 40% will have evidence 
of gluten sensitive enteropathy [Marks et al, 1970; Reunala et al, 1976].
The aim of this study, therefore, was to screen relatives of DH patients in three families 
in order to identify those with silent or latent coeliac disease. Families in which there was 
at least one additional member with DH or CD, over and above the index case, were 
chosen. Serology, small intestinal biopsy and evaluation of intraepithélial T cells 
expressing the y/ô cell receptor were used in the screening process. This study formed 
part of a larger project In which it was planned to look for gene linkage within these 
families.
2.3.2 Methods
Subjects
Ethical permission for this study was granted by St Mary's Hospital Local Ethics 
Committee.
Three families were identified and invited to participate via the index cases who attended 
the DH clinic at St Mary's Hospital. Consent was obtained from each individual family 
member. Family members were interviewed by myself and asked specifically about 
gastrointestinal and skin symptoms. I examined the skin of those patients volunteering 
skin symptoms. I took blood for serology from all those participating. Those family 
members who were identified as being potential carriers of the gene(s) and aged 16 years 
and over were offered duodenal biopsy, irrespective of their antibody results.
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Small intestinal biopsy
Serology
As a proportion of Individuals with CD exhibit IgA deficiency, all those participating had 
their IgA levels measured. In addition, ARA and AEA were measured and in order to 
ensure that the serology results were reproducible, a random selection of samples were 
sent to Helsinki, Finland where AGA and AEA estimations were performed in a blind 
manner by Dr Erkki Savilahti.
Morphometric analysis of small intestinal biopsies
Villous height: crypt depth ratios (VH:CD) and surface enterocyte cell heights (SECH) 
were measured by myself. I took care to avoid analysis of sections cut tangentially and to 
avoid analysis of mucosa overlying Brunner's glands [Shidrawi et a/, 1994]. The normal 
range for VH:CD was considered to be 3-5 whilst the normal range for SECH was 
considered to be 29-34 pm [Shidrawi etal, 1994].
Those who consented to small intestinal biopsy had biopsies taken from the second part of 
the duodenum via endoscopy. The small intestinal biopsies were performed by Dr Huw 
Thomas, Consultant Gastroenterologist at St Mary’s Hospital, Each participating individual 
had two sets of duodenal biopsies taken: one for routine histology and one which was 
snap frozen in OCT (Tissue Tek®) and stored at -70°C until processed - this latter set was 
used for evaluating intra-epithelial y/S T cells.
I
%
Intra-epithelial lymphocyte cell counts
I expressed the intra-epithelial lymphocytes per 100 epithelial cells. I performed counts on 
three sections and took the mean of these. I regarded values greater than 30 lymphocytes
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cells per 100 epithelial cells as being abnormal [Fry etal, 1974].
Intra-epithelial celts expressing the T ceil receptor
These were performed by Dr. Savilahti, Helsinki, as previously described [Savilahti et al, 
1990]. Positively staining cells were expressed per mm of surface epithelium. Values less 
than 7 cells per mm were regarded as normal [Savilahti et al, 1997].
2.3.3 Results
Seventy one individuals from 3 families participated and this included 8 who were already 
known to have DH (5) or CD (3) (Figures 2.4, 2.5, 2.6). Therefore, 63 "unaffected" 
individuals were interviewed, examined and had blood samples taken for serology. None 
of the "unaffected" relatives gave a history of significant gastrointestinal symptoms nor did 
they exhibit signs of malabsorption. After excluding those who had married into the family, 
48 were identified as being potential carriers, including 5 children. Forty three were offered 
duodenal biopsy and 23 accepted. A further patient, who was in fact the wife of one of the 
DH index cases (Figure 2.6: subject 11.10), was found to be positive for AGA-lgA, ARA and 
AEA and she too was offered duodenal biopsy. Therefore, a total of 24 individuals 
underwent endoscopy and duodenal biopsy at St Mary's Hospital, Paddington. An 
additional patient (Figure 2.4: subject 11.9), on learning that she was anti-endomysial 
antibody positive had an endoscopy arranged at her local hospital in Scotland by her 
General Practitioner.
Serology
No individual had IgA deficiency. Six individuals were identified as having positive 
seroiogy: 4 from family 1 (subjects 11.5, 11.9, 11.11, lll.l); 1 from family 2 (subject III.1); and
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1 from family 3 who was the wife of our index case (subject 11.10). The serology results are 
shown in detail in Tables 2.6, 2.7 and 2.8.
Villous height: crypt depth ratios, surface epithelial cell heights and intra-epithelial 
lymphocyte counts
Family 1 ( Figure 2.4 and Table 2.6)
One of the 4 participants with positive serology in this family (subject 11.11, T AGA-lgA) 
declined endoscopy. Of the remaining 3, subject 11.5 (T AGA-lgA) had a raised lEL count; 
subject 11.9 (EAE +ve), who had her duodenal biopsy performed at her local hospital, had 
normal villous architecture but raised lELs (formalin fixed sections were available for me to 
analyse); and subject lll.l (weak +ve ARA) had normal villous architecture and normal 
lELs. An additional family member (111.10), who had negative serology, was found to have 
a mildly raised lEL count (VH:CD not performed as all sections contained Brunner's glands 
in the sub-mucosa).
Family 2 (Figure 2.5 and Table 2.7)
In this family, one individual (lll.l)  was found to have circulating AEA and subsequent 
small intestinal biopsy demonstrated reduced VH:CD, reduced SECH and elevated lELs. 
One further individual (11.4), whose serology was negative, was also found to have a 
reduced VHiCD in the presence of normal SECH and a normal lEL count.
Family 3 (Figure 2.6 and Table 2.8)
In this family, one participating member (11.10), the wife of our index case, was found to 
have raised levels of AGA-lgA and to have circulating ARA and AEA. Small intestinal
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biopsy confirmed the presence of a reduced VH:CD, reduced SECH and elevated
numbers of lELs.
Intra-epithelial ceils expressing the y/g T ceil receptors
Family 1 (Figure 2.4 and Table 2.6)
Subjects 11.5, 1(1.1 and 111.16 were found to have raised levels of intra-epithelial T cells 
expressing the y/ô receptor. Subject 111,10, who had a raised lEL count, had normal levels 
of y/ô T cells, y/ô T cell estimations were not performed in subject 11.9.
Family 2 (Figure 2.5 and Table 2.7)
Subject lll.l who had positive serology, reduced VH:CD, reduced SECH and a raised lEL 
count In keeping with gluten sensitive enteropathy, was found to have elevated numbers of 
T cell expressing the y/ô receptor. One further participant (11.4), whose serology was 
negative but who had a reduced VH:CD suggestive of mild GSE, had elevated numbers of 
y/ô T cells.
Family 3 (Figure 2.6 and Table 2.8)
Subject 1.3, whose serology was negative and whose VH:CD, SECH and lEL count were 
normal, had elevated numbers of T cell expressing the y/ô receptor. Subject 11.10, who had 
positive serology, a reduced VH:CD, reduced SECH and an elevated lEL count, was 
found to have elevated numbers of y/ô T cells.
Summary of results
Family 1. (Figure 2.4) Thirty three individuals participated of whom 7 were considered to 
be carriers for the gene(s) for DH/CD and this Included 3 previously identified as having
61
DH (2) or CD (1). Of the additional 4 individuals identified during the study, 3 were found to 
have an elevated y/5 T cell count (11.5, III.1 and 111.16) and in two (III.1 and 111.16) this was 
the only abnormality detected indicating that they had latent coeliac disease. Participant
11.5 had a raised lEL count accompanying an elevated y/5 T cell count. Unfortunately, 
subject 11.9 did not have y/ô T cell evaluations performed as her biopsy was performed in 
Scotland; in view of the fact that her lEL count was greatly elevated in the presence of a 
positive AEA, we felt it very likely that she was a carrier.
Subject 111.10 had an isolated borderline elevated lEL count and in the absence of any 
further supportive features, it seemed unlikely that he was a carrier. I was unable to 
explain this isolated finding.
Looking at the family tree for Family One (Figure 2.4), if it is assumed that the gene(s) is 
inherited in an autosomal dominant fashion, then it seems likely that family members 11.1 
and 11.3 were also silent carriers.
Thus, of the 33 individuals investigated, 7 appeared to be definite carriers with a possible 
further 2 by deduction. After excluding those who had married into the family, (I.e. 7 
individuals), the carrier rate for this family appeared to be 7/26 or 27%; or, if we also 
consider subjects 11.1 and 11.3 as carriers, then the rate becomes 9/26 or 35%.
Family 2. (Figure 2.5) Eight individuals participated and 4, Including the father and son 
who were already known to have DH, were found to be affected. After excluding the wife 
of the propositus, the carrier rate was 4/7 or 57%.
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Family 3. (Figure 2.6) Thirty individuals participated and 5 were found to be affected. This 
included subject 1.3, who was aged 75 years at the time of the study and who was found to 
have elevated numbers of lELs expressing the y/5 T cell receptor indicating that she had 
latent CD or was a gene carrier. The wife of the propositus was also demonstrated as 
having CD (11.10).
Thus, after excluding those who had married into the family and subjects III.3-6, III.9 and
■■
111.11-15 as I believed them to be true negatives as NO evidence of CD was detected in 
their parents, the carrier rate for this family was 3/13 or 23%.
2.3.4 Discussion
This study, which was part of a larger study which aimed to look for gene linkage for 
DH/CD within families, has confirmed that so called healthy relatives of patients with DH 
have a significant risk of silent or latent coeliac disease, it has also demonstrated that 
screening families of DH patients by means of serological testing alone is not wholly 
reliable in excluding CD. CD can only be absolutely excluded following morphometric
evaluation of small intestinal mucosa, enumeration of lEL counts and of lELs bearing the 
y/ô T cell receptor.
Serological testing for CD using AGA, ARA and AEA can be useful in screening large
,
populations and can pinpoint those individuais who warrant further investigation by means 
of smali intestinai biopsy. Indeed, recent reports, in which populations have been screened 
using these antibodies, have highlighted the fact that there are many individuals with 
hitherto undiagnosed CD [Catassi etal, 1994; Unsworth & Brown, 1994]. AGA (ciass IgA), 
which is detected using an enzyme-linked immunosorbent assay (ELISA), has a high
sensitivity in the diagnosis of CD but a low specificity as it may be present in normal 
individuals [Savilahti et al, 1983], ARA and AEA are both IgA antibodies. The first 
publications on ARA appeared in 1971 and it was noted that it had a lower sensitivity but 
higher specificity than AGA-lgA in the detection of CD [Seah et ai, 1971; Seah et al, 1971], 
Later, a further antibody was discovered, AEA, and it was shown to have a sensitivity and 
specificity similar to ARA, with the latter approaching 100% in DH and CD [Beutner et al, 
1986; Chorzelski et al, 1984], ARA and AEA are more likely to be positive in individuals 
with more severe forms of villous atrophy and negative in patients with milder forms 
[Leonard et al, 1985; Beutner et al, 1986; Reunala et al, 1987; Hallstrom, 1989], Thus, 
given that the presence of ARA and AEA is dependent on the severity of the villous 
atrophy, screening with these antibodies alone would fail to detect those with mild 
enteropathy or those with latent CD.
It has recently been demonstrated that patients with CD and DH have increased 
numbers of intra-epithelial cells bearing y/6 T cell receptors [Spencer et al, 1989; 
Halstensen et al, 1989; Savilahti et al, 1990; Savilahti et al, 1992] and that these cells 
remain elevated even when patients adhere to a gluten free diet [Savilahti et al, 1992]. 
Moreover, it has been shown that patients with elevated numbers of y/5 T cells and normal 
villous architecture are at risk of developing CD i.e. they have latent CD [Maki etal, 1991], 
or of developing DH [Savilahti et al, 1992]. It is not known if T cells bearing the y/5 receptor 
are involved in the pathogenesis of the enteropathy of CD or whether they simply indicate 
a genetic susceptibility to develop CD and DH. It has been demonstrated that elevated 
numbers of intra-epithelial y/5 T cells are associated with HLA DQA and DOB, genetic 
markers for CD and DH, and furthermore, the greater number of these gene markers 
present within an individual, then the more likely they are to have elevated y/5 T cell counts
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[Holm etal, 1992].
In conclusion, the families studied here support a genetic basis for DH and CD and in 
particular, an autosomal dominant mode of Inheritance, which is in agreement with others 
[Reunala, 1996]. Finally, genetic studies, which aim to look for gene linkage, should not 
rely solely on serology but should also perform small intestinal biopsies, lEL and lEL y/5 T 
cell counts wherever possible.
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TABLES 2.6, 2.7 AND 2.8: serology; morphometric analysis of small 
intestinal biopsies including villous height: crypt depth ratios and surface 
enterocyte cell heights; intra-epitheiial lymphocyte counts; and counts of T cells 
bearing the y/5 receptor.
Key to tables:
lELs intra-epithelial lymphocyte counts
ND not done
AGA-lgA anti-giladin antibodies, class IgA
AEA anti-endomysial antibodies
DH dermatitis herpetiformis
CD coeliac disease J
'I
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TABLE 2.6: Family one
SUBJECT SEROLOGY D2 BIOPSY
VH:CD SECH lELs y/8T
CELLS
11.1 negative ND ND ND ND
11.2 negative ND ND ND ND
11.3 negative ND ND ND ND
11.4 negative ND ND ND ND
11.5 AGA-lgA ( Î  ) 4.2 35 4 7 ( f ) 1 5 ( f )
11.6 negative ND ND ND ND
11.7 negative ND ND ND ND
11.9 AEA +ve 3.8 29 49 ( T ) ND
11.10 negative ND ND ND ND
li.11 AGA-lgA ( t  ) ND ND ND ND
lll.l ARA weak 
+ve
3.9 30 14 15.8 (T )
III.2 negative ND ND ND ND
III.3 negative 3.5 34 14 0.6
III.4 negative 4.9 35 18 2.7
III.5 KNOWN DH
III.6 negative ND ND ND ND
III.7 KNOWN DH
III.8 KNOWN CD
III.9 negative ND ND ND ND
111.10 negative ND 31 33 (T ) 1.5
111.11 negative 3.1 31 7 0
111.12 negative ND ND ND ND
111.13 negative ND ND ND ND
111.14 negative 5.6 29 26 0
111.16 negative 5.1 34 16 33.3 ( T )
IV. 1 negative ND ND ND ND
IV.2 negative ND ND ND ND
IV.3 negative ND ND ND ND
IV.4 negative ND ND ND ND
IV.5 negative ND ND ND ND
IV.6 negative ND ND ND ND
IV.7 negative 6.2 33 14 1.4
IV.8 negative 2.9 31 11 2
TABLE 2.7: Family two
SUBJECT SEROLOGY D2 BIOPSY
VH:CD SECH lELs y/ôT
CELLS
1.1 negative ND ND ND ND
11.1 negative 3.8 31 11 6
11.2 KNOWN DH
11.3 negative ND ND ND ND
11.4 negative 2 .5 (1 ) 31 22 8.3 ( T )
lll.l AEA +ve 1 . 8 ( 4 ) 2 3 ( 4 ) 4 4 ( t ) 1 2 ( T )
III.2 KNOWN DH
III.3 negative 3.5 36 28 2.5
f
a?
JVj
TABLE 2.8: Family three
SUBJECT SEROLOGY D2 BIOPSY
VH:CD SECH lELs y/ôT
CELLS
1.3 negative 3.3 32 12 2 3 ( f )
1.4 negative ND ND ND ND
11.2 K NOWN CD
11.3 negative ND ND ND ND
11.4 negative 3.3 32 8 ND
11.6 negative 3.9 38 11 5
11.7 negative ND ND ND ND
ii.g K NOWN DH
11.10 AGA-lgA T 
ARA +ve 
AEA +ve
0.3 ( 4 ) 2 0 ( 4 ) TTT 7 ( f )
11.11 K NOWN CD
11.12 negative ND ND ND ND
11.13 negative 3.7 34 16 0
11.14 negative ND ND ND ND
11.15 negative 3.7 31 11 5
11.16 negative ND ND ND ND
11.17 negative 3.7 36 10 1
lll.l negative ND ND ND ND
III.2 negative ND ND ND ND
III.3 negative ND ND ND ND
111.4 negative ND ND ND ND
III.5 negative ND ND ND ND
III.6 negative ND ND ND ND
III.7 negative 3.6 34 16 1
lli.8 negative 4.2 32 8 0
III.9 negative ND ND ND ND
111.11 negative ND ND ND ND
111.12 negative 4.6 33 18 3
111.13 negative ND ND ND ND
111.14 negative ND ND ND ND
111.15 negative ND ND ND ND
Key to Figures 2.1, 2.2 and 2.3.
CD
.CD  ___  DH
NI _  NI
serology only obtained; 
no intestinal biopsy performed
small intestinal biopsy normal
reduced villous height : crypt depth ratio (VH : CD) 
(normal range : 3-5)
reduced surface enterocyte cell height (SECH)
(normal range : 29-34 pm)
raised intra-epithelial lymphocyte count (lEL)
(normal range : < 30 per 100 epithelial cells)
raised numbers of intra-epithelial cells y/ô T cell receptor 
(normal range : < 7 per mm)
known to have either 
dermatitis herpetiformis (DH) or 
coeliac disease (CD) prior to study
not investigated
FIGURE 2.1: Family one
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FIGURE 2.2: Family two
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CHAPTER 3 
LABORATORY STUDIES
1. SKIN TESTING WITH GLUTEN IN PATIENTS WITH DERMATITIS 
HERPETIFORMIS
3.1,1 Introduction
Patients with dermatitis herpetiformis (DH) have an enteropathy which is indistinguishable 
from gluten sensitive enteropathy (GSE). T cell mediated mechanisms have been 
implicated in the pathogenesis of GSE because of the similarity between the histological 
features of GSE and graft versus host disease (GvHD) [Nieid, 1981] and the characteristic 
finding of elevated numbers of intra-epithelial lymphocytes (lELs) in the small intestine of 
patients with CD and DH which decrease during a gluten free diet (GFD). Furthermore, 
normal foetal small bowel, exposed in vitro to T cell activators, develops villous atrophy 
and crypt hyperplasia [MacDonald, 1988]. Moreover T cell responses have been 
demonstrated both in the peripheral blood [Sikora et al, 1976; O'Farrelly et al, 1982] and 
more recently in the small intestinal mucosa [Lundin et al, 1993] of patients with coeliac 
disease. It has been postulated that GSE is due to a breakdown of the normal 
immunological mechanisms which ensure oral tolerance to gluten [Mowat, 1987].
Previous studies of intradermal skin testing in CD and DH [Anand et al, 1977; Logan & 
Ferguson, 1978; Marks & Young, 1978] using the saline soluble enzyme digest of gluten 
"Frazer's fraction III" [Frazer et al, 1959] provoked "Arthus" type reactions at 6 hours in 
patients and also in many control subjects, but delayed type hypersensitivity (DTH) 
responses were not seen clinically. The absence of DTH responses was surprising if the
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postulated T cell pathogenesis of GSE is correct. Many of the patients in these previous 
studies who gave "Arthus" like reactions had been on a strict GFD for many months and 
so presumably gluten antibody negative arguing against a local immune complex type 
reaction. Unfortunately, antibody studies were not conducted in the above mentioned 
studies.
Recent rectal challenge studies in CD using FFIII as antigen [Loft et al, 1990] revealed 
that CD patients showed increased lELs on biopsy as early as 6 hours whilst the majority 
of disease controls did not. It could be postulated that intradermal testing with FFIII might 
lead to a sub-clinical T cell influx into the skin in gluten sensitive patients. Furthermore, 
FFIII has been shown to be a potent activator of complement via the alternative pathway 
in vitro and it has been proposed that this property may be involved in the pathogenesis of 
GSE [Unsworth et al, 1993]. This led me to perform the present pilot study of intradermal 
testing with FFIII: biopsies were taken at 6 hours and 48 hours and processed 
immunohistologicaliy for T cell infiltration. I chose patients so as to include those with and 
without anti-gluten antibody.
3.1.2 Methods I
Patients and controis
Ethical permission for this study was granted by St. Mary's Hospital Local Ethics 
Committee. Three normal volunteers (2 males, 1 female) and six patients (4 males, 2 
females) with DH were enrolled in the study. Three of the DH patients were controlled by 
gluten free diet (GFD) alone and had been taking their diets for a mean of 8 years (range 
6 - 1 1  years): gut biopsies in two of these patients were normal and not available in the 
third. The other three DH patients were taking normal diet and required dapsone for
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taken.
disease control: gut biopsies were abnormal in these patients with one having partial 
villous atrophy and two severe villous atrophy. I asked the patients who required dapsone 
for disease control to discontinue their dapsone 48 hours before attending for their 
intradermal injections and asked them not to restart it until after the biopsies had been
I
Preparation of Frazer's fraction III
Frazer's fraction III was prepared by my co-worker Dr Joe Unsworth (Consultant 
Immunologist, Regional Department of Immunology, Southmead Hospital, Bristol) as 
previously described [Frazer et al, 1959], Wheat gluten (SIGMA Chemicals Ltd) was 
dissolved in sterile phosphate buffered saline pH 7.2 at lOmg/ml (phenol was omitted). 
Microbiological assessment prior to use showed the preparation to be free of bacterial and 
fungal contaminants. The preparations were frozen at -20° until used. Confidence that the 
FFIII prepared was of good quality was based on the fact that it bound In vitro to reticulin 
in rat tissue sections and the fact that patients with active but not treated coeliac disease 
gave high titres in the FFIII ELISA assay [Unsworth etal, 1985].
Intradermal skin testing and skin biopsies
I Injected 50pl of phosphate buffered saline (PBS) control or FFIII intradermally into the 
flexor surface of each forearm. Two of the patients with DH with enteropathy had an 
additional site on one forearm injected with FFIII. I marked the sites of injection and 
monitored these at regular intervals for the first 8 hours and then at 48 hours: patients
.
were asked to note any skin changes at the injection sites between 8 hours and 48 hours.
I took 4mm punch biopsies from the PBS and FFIII injected sites at 48 hours. In addition, I 
took biopsies in two patients from FFIII injected sites at 6 hours. The skin biopsies were
80 s
snap frozen and stored in liquid nitrogen. Later, I cut 6pm sections using a cryostat (Slee,
London).
I
;
I used a battery of common recall antigens (Multitest CM!, Pasteur Mérieux) consisting 
of streptococcus, old tuberculin, Candida albicans, trichophyton mentagrophytes and 
proteus mirabilis antigens and a control of glycerin and applied this battery intradermallly
'
by multipuncture to the flexor aspect of the forearms. I assessed these clinically at 48 
hours.
81
'7:1
I
EUSA assays
An ELISA for anti-FFIII and anti-gliadin antibodies was performed as described previously 
by my co-worker Dr Joe Unsworth [Unsworth et al, 1985].
Immunoperoxidase staining
I performed immunostaining on the skin sections using the avidin-biotin peroxidase 
technique: I used a Vectastain Elite ABC kit (Vector Laboratories, Peterborough) and 
Becton Dickinson (USA) monoclonal antibodies to stain for CDS (pan T cell), CD4 (helper 
T cell) and CD8 (suppressor/cytotoxic T cell). Briefly, I air dried the sections, fixed them in 
acetone and then blocked them using normal serum. I quenched endogenous peroxidase 
with 0.3% HgOg in methanol. I then incubated the sections with primary mouse monoclonal 
antibodies followed by biotinylated horse anti-mouse secondary antibodies. Following this,
;
I incubated the sections with the avidin-biotin peroxidase complex and developed the
colour reaction with the substrate 3-amlno-9-ethyl-carbazole (AEC) tablets (Sigma, USA). 
Finally, I counterstained the sections with haematoxylin and mounted them in glycergel
(Dako).
Immunofiuorescent staining
A neoepitope exposed in human terminal complement complex, and recognised by a 
mouse monoclonal antibody (Dakopatts: Dako-C5b-9, ae11), was used to detect 
complement activation product by indirect immunofluorescence with a fluorescein labelled 
rabbit anti-mouse Ig reagent (Dakopatts) in the second layer. This was performed by my 
colleague Dr Joe Unsworth.
Quantitation of T ceils
My colleague, Dr Barbara Baker coded the slides containing the skin sections. I then 
counted positively staining cells in the upper dermis in a blind manner in 4-6 sequential 
high power fields (x400) in two sections. Statistical analysis was not performed due to the 
small number of subjects and controls.
3.1.3 Results
Anti-gliadin antibodies
The three controls had anti-gliadin antibodies (AGA) within the normal range (optical 
density values: IgA < 0.3, IgG < 0.75). The three DH patients who were taking a normal 
diet had elevated levels of IgA AGA whereas the three DH patients taking a gluten free 
diet had IgA AGA within the normal range (Table 3.1).
Clinical assessment
Intradermal injection of FFIII produced a wheal and flare reaction within a few minutes of 
being injected in all 6 patients and in the 3 controls - this persisted for up to 6 hours. 
Injection of PBS as control did not cause these early lesions in either the patients or 
controls. No skin changes were reported to have occurred in either group between 8 and
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48 hours. Patients and controls reacted to one or more of the recall antigens present in the 
battery and there was no difference between the groups (Table 3.2).
Histological assessment/lymphocyte counts
No increase In the number of T lymphocytes was observed in the biopsies taken from FFIII 
injected sites at 6 hours or 48 hours compared with the PBS injected lesions. The wheal 
and flare reaction had subsided by the time of biopsy in the two patients who had biopsies 
taken at 6 hours. The T lymphocyte counts are shown In Table 3.3.
Detection of terminal complement component (TCC)
TCC was absent in the biopsies taken at PBS and FFIIi injected sites in two of the 
controls. However, TCC was found to be present in biopsies taken at PBS and FFIII (6 
hours and 48 hours) in each of two of the DH patients tested.
3.1.4 Discussion
GSE is thought to be due to T ceil mediated mechanisms [Nieid, 1981; MacDonald, 1988]. 
It has been postulated that there is a breakdown of oral tolerance mechanisms in CD and 
DH [Mowat, 1987]. Therefore, it might be expected that intradermal injection of FFIII might 
lead to an influx of T cells sensitised to FFIIi to the skin with subsequent development of a 
delayed hypersensitivity response. This study failed to demonstrate this. Cell mediated 
immunity appeared to be intact in the subjects studied since they did mount responses 
clinically to common recall antigens.
It is possible that failure to elicit a response following intradermal injection of FFIII was 
due to too low a concentration of antigen being used. This is unlikely since our laboratory
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has previously shown that both peripheral blood and gut T lymphocytes from DH patients 
respond to the antigen at 1 mg/ml in vivo [Baker et al, 1995]. Another possibility is that the 
antigen given was not in a form suitable to allow processing and presentation to T cells by 
antigen presenting cells in the skin. A third explanation is that the antigen may have 
cleared from the site of injection before an immune response could develop; again this is 
improbable as FFIII is a large complex molecule which would not be expected to clear 
quickly from the skin.
The wheal and flare response obtained in both patients and controls is intriguing and has 
been noted before [Logan & Ferguson, 1978; Marks & Young, 1978]. It has previously 
been hypothesized that this represents an Arthus response (type III hypersensitivity) 
[Anand et ai, 1977]. However, this seems unlikely as in the group of patients studied here, 
even those with undetectable anti-gliadin antibody demonstrated this phenomenon. 
Moreover, the response occurred in normal individuals with trivial levels of antibody. An 
alternative hypothesis is that injection of FFIII intradermally leads to activation of 
complement with a resultant wheal and flare reaction. It has recently been demonstrated 
that FFIII is Indeed a strong activator of complement via the alternative pathway [Unsworth 
et ai, 1993] and this property of FFIII may be involved In the pathogenesis of GSE. The 
absence of TCC in the biopsies taken from the controls injected with FFIII and the failure 
of this study to demonstrate increased amounts in DH skin after FFIII injection detract from 
the hypothesis.
T lymphocytes are found in significantly increased numbers in lesional DH skin 
compared with non-lesional DH skin [Nestor et al, 1987; Garioch et al, 1994] and I have 
found that many are activated [Garioch etal, 1994]. The contribution of these T cells in the
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pathogenesis of DH skin lesions is unknown. It seems unlikely that these T cells are 
specific for FFIII as Intradermal injection of FFIII failed to result in an increase in the 
number of T cells in the skin or the production of delayed hypersensitivity. Furthermore, 
previous experiments in our laboratory have failed to demonstrate proliferation of T cells 
from DH lesional skin to FFIII [Baker et al, 1995]. If these T cells are involved in the 
pathogenesis of DH skin lesions, it is more probable that they are specific for an 
unidentified antigen present in the skin.
Thus, if GSE is T cell mediated, then failure to provoke DTH by intradermal skin testing 
of patients known to be gluten sensitive suggests that the T cells concerned are mucosally 
associated and unable to migrate to the skin.
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t a b le  3.1 ; Optical density measurements of anti-gliadin antibodies in 
dermatitis herpetiformis patients
Patient IgG IgA Gut biopsy Diet
PI <0.75* 0.36 (t) SVA normal
P2 <0.75* 0.35 (t) PVA normal
P3 1.7 ( t) 1.1 ( t) SVA normal
P4 1.15 (t) <0.1* not done GFD
P5 <0.75* <0.1* normal GFD
P6 <0.75* <0.1* normal GFD
*undetectable (i.e. sub-normal) levels of IgG and IgA antibody. 
Normal range: IgG < 0.76; IgA <0.1.
P
SVA
PVA
GFD
patient
severe villous atrophy 
partial villous atrophy 
gluten free diet
Ï
I
i
I
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ITABLE 3.2: Clinical response to a battery of recall antigens in controls and 
dermatitis herpetiformis (DH) patients at 48 hours (+ = positive response; - = 
negative response)
Controls ____________ DH patients
C1 C2 C3 P1 P2 P3 P4 P5 P6
ANTIGEN
Tetanus toxoid + + + + + + + 4*
Diptheria toxoid - - + + + - + - 4-
Strep Grp C - - - “ + - + 4- -
Tuberculin + + - + + - + + 4-
Candida albicans + + - _ - - - + 4-
T, mentagrophytes - - - + - - + - 4*
Proteus mirabilis - + + - - - + 4- 4-
Glycerin (control) - -
C control
P patient
:
TABLE 3.3: Mean number of lymphocytes per high power field (x400) ± 
standard error of the mean
CDS CD4 CDS
DH patients (n = 6)
PBS biopsies (48 h) 17 + 4 7 + 1 14 + 4
FFIII biopsies (48 h) 18 + 6 13 + 7 10 + 5
DH patients (n = 2)
FFIII biopsies (6 h) 12 + 2 10 + 7 5 + 1
Controls (n = 3)
PBS biopsies (48 h) 19± 16 11 ±9 4 + 2
FFIII biopsies (48 h) 24 + 7 12 + 2 7 ± 3
n number of patients
PBS phosphate buffered saline
DH dermatitis herpetiformis
FFIII Frazer’s fraction III
CD3 pan T cell
CD4 helper T cell
CD8 suppressor/cytotoxic T cell
Note: Statistical analysis was not performed due to small number of controls and 
subjects.
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CHAPTER 3 
LABORATORY STUDIES
2. T LYMPHOCYTES IN LESIONAL SKIN OF PATIENTS WITH 
DERMATITIS HERPETIFORMIS
3.2.1 Introduction
it has previously been postulated that DH is an immune complex disorder because it is 
often associated with raised levels of immune complexes composed of IgA [Mowbray et al, 
1973; Zone et al, 1980; Vainlo et al, 1983; Hall & Lawley, 1985]. However, this hypothesis 
fails to explain: 1) the absence of skin lesions in uninvolved skin although IgA is present; 
2) why disease activity is not related to the level of circulating immune complexes 
[Mowbray et al, 1973]; and 3) why it takes two years for the rash of DH to clear after 
patients have been commenced on a GFD [Fry et al, 1973; Fry et al, 1982]. It is possible, 
therefore, that other immunological mechanisms are involved in the pathogenesis of DH. 
Perivascular cellular infiltrates composed mainly of T lymphocytes were shown to be
characteristic of developing lesions induced by application of potassium iodide patch tests 
in patients with DH [Reitamo et al, 1981]. Recently it has been shown that certain 
cytokines may be involved in the development of skin lesions of DH [Graeber et al, 1993].
The aim of this study was to quantitate the T cells in involved and uninvolved skin taken 
from patients with DH and to investigate their distribution and state of activation. The 
distribution of GDI a positive dendritic cells was also studied.
3.2.2 Methods
Patients
Ten patients with DH controlled by sulphones and/or sulphonamides were asked to stop 
their nnedication and I took two 4mm punch biopsies 2-4 days later: one from involved skin 
and the other from un involved skin. Seven of the "involved" biopsies were from clinically 
urticated lesions and 3 were from small vesicles: 3 of the urticated lesions showed 
subepiderma! blisters microscopically. I then snap froze the skin biopsies in OCT (Tissue 
Tek®) and stored them in liquid nitrogen. Later, I cut 6pm sections using a cryostat (Slee. 
London) and stored them at -80°C until staining.
Immunoperoxidase staining
I used the avidin-biotin peroxidase technique (as described in section 3.1.2) and 
monoclonai antibodies to stain for CD3, CD4, CDS, CD25, CD la  and CD45RO. All 
monoclonal antibodies were obtained from Becton-Dicklnson (Oxford, UK) with the 
exception of 0KT6 specific for CDIa (Orthodiagnostics Systems Ltd., High Wycombe, 
Bucks). I stained control sections in an identical manner except for omission of the primary 
monoclonal antibody.
Double labelled immunofluorescent staining
I used a 5 layered method to stain simultaneously for CD3 and HLA-DR in involved skin 
[Baker et al, 1984]. Briefly, I air dried the sections and fixed them in acetone:chloroform 
(50:50). I initialiy incubated the sections with mouse monoclonal antibody to CD3 (Becton- 
Dlckinson, Oxford, UK) followed by incubation with biotin labelled horse-anti-mouse 
antibody and then streptavidin-texas red (Amersham, UK), I then incubated the sections 
with the monoclonal rat-anti-DR antibody (Dako, High Wycombe, Bucks) and finally with
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rabbit-anti-rat-FlTC (Sigma, Poole, Dorset). I mounted the slides in 10% phosphate 
buffered saline in glycerol with 2.5% 1,4-diazablcyclo(2.2.2.)octane (DABCO) (Sigma, 
Poole, Dorset) added to prevent quenching of the FITC.
Quantification
I counted positively stained cells in 4-6 consecutive high power fields (x400) in 2 sections 
and expressed these per high power field. By comparing control sections with stained 
sections, I excluded neutrophils, which may have stained non specifically with the avidin- 
biotin complex.
Statistics
I used the Mann Whitney U test to compare the T cell counts in involved skin with those in 
uninvolved skin.
3.2.3 Results
T lymphocyte counts
I found that the number of CD3 positive lymphocytes was significantly increased in the 
upper dermis of involved compared with uninvolved skin (p < 0.0005) (Table 3.4). Clumps 
of T lymphocytes were in a perivascular distribution in the upper dermis but were not 
observed within the epidermis nor in the dermal papillae whereas neutrophils were largely 
confined to the tips of the dermal papillae. The majority of these T cells were CD4 positive 
and they exceeded the number of CDS positive T cells by a ratio of 4:1. There was also a 
significant increase in the number of CD45RO positive memory T cells, in involved 
compared with uninvolved skin (p < 0.0005). The total number of CD45RO positive cells 
was greater than the total number of CD3 positive cells, presumably due to staining of
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CD45RO on small numbers of neutrophils, monocytes and macrophages which also had a 
perivascular distribution. Staining with CD25 was not detected in either Involved or 
uninvolved skin.
Double labelling of CDS positive cells showed that approximately 20-40% also 
expressed HLA-DR (Figure 3.1).
CD1 positive celis
I observed that CDIa positive cells appeared to be present in the epidermis of both 
involved and uninvolved skin in similar numbers (numbers not counted). However, CD1a 
positive cells were also present in the dermis of involved skin in 9 out of the 10 patients: 
these cells were admixed with the perivascular collections of T lymphocytes (again, 
numbers not counted) (Figure 3.2). I found no CDIa positive cells to be present in the 
dermis of uninvolved skin.
3.2.4 Discussion
This study has shown that there is a significant increase in the number of T lymphocytes in 
the upper dermis of involved compared with uninvolved skin in DH. These lymphocytes 
were arranged around the blood vessels in the upper dermis and were composed mainly 
of CD4 positive memory T cells. Furthermore, a proportion expressed HLA-DR antigens 
but, surprisingly, were CD25 antigen negative. The differential expression of CD25 and 
HLA-DR expression may be due to differences in kinetics of expression of these two 
activation molecules. The CD25 monoclonal antibody used in this study stained T cells of 
chronic plaque psoriasis using the same method excluding the possibility that it was not 
functioning properly. In addition, CDIa positive Langerhans’ cells were found in close
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association with the T lymphocytes in involved skin suggesting interaction between the two 
cell types. A previous study of mononuclear cell infiltrates In bullous diseases also found a 
significantly increased number of T cells in the dermis of involved compared with 
uninvolved DH skin [Nestor et al, 1987]. However, this previous study did not examine 
markers of T cell activation and, in contrast with my study, found that 
LangerhansVdendritic ceils were absent from the dermis of involved DH skin. This variation 
in results could be due to the fact that a two layered method of immunostaining was used 
in contrast with the more sensitive three layered method I used.
The role of these activated T cells in the pathogenesis of DH skin lesions is open to 
speculation. One possibility is that they enter the skin early and, via the secretion of 
cytokines such as interferon-y, tumour necrosis factor-a or interleukin-2, cause neutrophils 
and eosinophils to leave the blood vessels, enter the dermis and become activated. A 
study [Graeber etal, 1993] performed in our department demonstrated interleukin-8 (IL-8) 
on basal epidermal cells and granulocyte macrophage-colony stimulating factor (GM-CSF) 
on dendritic cells at the dermo-epidermal junction of involved skin in DH. It has been 
proposed that the neutrophils migrate towards the tips of the dermal papillae because of 
the presence of the chemo-attractant IL-8 on basal epidermal cells and bind to the IgA 
once activated by GM-CSF expressed by dendritic cells at the dermo-epidermal junction 
[Graeber et al, 1993]. However, it is difficult to determine whether T lymphocytes enter the 
dermis prior to neutrophils in DH, Unfortunately, there are no suitable models available 
which would allow time course studies to be performed. Although the application of 
potassium iodide patch tests in patients with DH produces lesions which are clinically and 
histologically indistinguishable from DH [Reitamo et al, 1981], the mechanisms involved 
must differ from those involved in spontaneous evolution of lesions as IL-8 has not been
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far, to demonstrate proliferation of these T cells to Frazer's fraction III (the partial peptic 
tryptic digest of gluten which is antigenic) (unpublished observations). It is possible that 
these T cells are specific for a component of the skin.
In conclusion, T lymphocytes may play a role in the pathogenesis of the skin lesions in 
DH via production of cytokines. Further work Is required to elucidate the antigen specificity 
of these cells.
-I
detected in lesions induced by application of potassium iodide patch tests (unpublished 
observations).
The close association of T cells and Langerhans’ cells and the expression of HLA-DR 
antigens by a proportion of the T cells suggest that a cell mediated immune response is 
taking place in the DH skin lesion. However, the antigen specificity of the T cells in the 
involved skin of DH is unknown. Preliminary experiments in our laboratory have failed, so
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FIGURE 3.1: Double-labelled immunofluorescent staining of the upper dermis in 
lesional dermatitis herpetiformis skin for (a) CD3, and (b) HLA-DR membrane 
staining. The arrows indicate some examples of double=labelled T lymphocytes 
(x400).
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FIGURE 3.2: immunoperoxidase staining of the upper dermis in iesionai 
dermatitis herpetiformis skin for (a) CDS, and (b) CD1a membrane expression 
(x400).
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t a b l e  3 .4 : Mean lymphocyte counts in the upper dermis per high power field 
(x400)
Uninvolved (n = 10) Involved (n = 10)
CD3 6 (SEM± 1) 41 (SEM ±12)*
CD4 5(SEM±1) 39 (SEM ±13)**
CDS 4(SEM±1) 10 (SEM ±2)***
CD45RO 7{SEM±1) 53 (SEM ±15)*
CD4:CD8 1:1 4:1
i
*p
**p
SEM
< 0.0005 compared with uninvolved
< 0.002 compared with uninvolved
< 0.05 compared with uninvolved 
standard error of the mean
Note: Numbers of CD1a positive cells not evaluated.
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CHAPTER 3
LABORATORY STUDIES
3. RESTRICTION OF T CELL RECEPTOR Vp EXPRESSION IN 
DERMATITIS HERPETIFORMIS SKIN
3.3.1 Introduction
It has previously been hypothesised that the skin lesions of DH are due to T cell mediated 
responses directed against an as yet unidentified autoantigen [Baker et al, 1995]. 
Restricted T-cell receptor V(3 gene expression would support the hypothesis that 
recognition of a specific antigen(s) or superantigen is important in the pathogenesis of DH 
skin lesions. Restricted expression of T-cell receptor Vp genes has been demonstrated in 
other disorders such as rheumatoid arthritis [Miltenberg etal, 1990; Sottini et el, 1991] and 
sarcoidosis [Moller et al, 1988]. Previous work from our department demonstrated 
restriction of the T-celi receptor Vp gene expression in patients with psoriasis [Lewis et al, 
1993]. The aim of this study, therefore, was to examine the expression of T-cell receptor 
vp genes in the skin of patients with DH using monoclonal antibodies and an 
immunoperoxidase technique.
3.3.2 Methods
Patients and samples
Approval for this study was granted by St Mary's Hospital Local Ethical Committee. Patient 
consent was also obtained prior to skin biopsies and blood samples being taken.
Ten patients (mean age 54 years, range 27-71) with DH controlled by dapsone and/or
I
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suiphonamides were enrolled in the study. Of these patients, 8 were taking a normal diet 
and 2 a strict gluten free diet (GFD) but had not yet managed to control their rash with diet
Immunoperoxidase staining
I used the avidin-biotin peroxidase technique, as described in section 3.1.2, to stain the 
skin sections. Control sections included substitution of the primary antibody with a mouse
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alone. I asked patients to discontinue their medication and I took two 4-mm punch biopsies 
7 days later: one from a blister and the other from uninvolved skin, a few centimetres from 
the involved site. I then snap froze the skin biopsies in OCT (Tissue Tek®) and stored them 
in liquid nitrogen. Later, I cut 6 jxm sections using a cryostat (Slee, London), and stored the 
sections at -80°C until staining.
Peripheral blood lymphocytes (PBL) were isolated from 20 ml of heparinised blood by 
Ficoll-Hypaque density gradient centrifugation by my colleague, Dr Barbara Baker.
Antibodies
I used monoclonal antibodies which had been shown to recognise specifically a variable 
region epitope on the p chain of the following Vp families: Vp2, Vp8 (both kindly donated 
by Professor Boylston, University of Leeds), Vps (a gift kindly donated by Dr. M. Owen, 
ICRF [Viney et al, 1992]), VpS.1, Vp5.2/5.3, Vp5.3, Vp6.7, Vpi2.1, Vp13.1/13.3 (T-Cell 
Sciences Inc., Cambridge, MA, U.S.A.), Vp2, Vp9 and Vp17 (Immunotech, Marseille, 
France). Other antibodies used were pan ap (T cell Sciences Inc., Cambridge, MA, 
U.S.A.) and CD3 (Becton Dickinson, Oxford, U.K.). All primary antibodies were used neat 
with the exception of Vp9 and Vpi7 which were used at dilutions of 1:10 and 1:5 
respectively.
Quantification
The slides were coded by my colleague Dr Barbara Baker following which I counted 
positively stained cells in four to six consecutive high power fields (x400) in two sections in 
a blind manner.
In addition, I compared Vp TCR expression in the skin with peripheral blood using
102
IgG isotype control antibody (Vector laboratories, Peterborough, UK) and omission of the 
primary antibody.
Flow cytometric analysis
Flow cytometric analysis was performed by Dr Barbara Baker on PBL obtained from the 
DH patients at the time of biopsy. PBL were separately incubated with each anti-ICR Vp 
antibody (all used neat with the exception of pan ap, Vp9 and Vp13.1/13.3 antibodies 
which were used at a dilution of 1:2) and followed by FITC-labelled sheep anti-mouse IgG 
antibody (Sigma) diluted 1:10 and double stained for CD3 expression with phycoerythrin- 
conjugated Leu 4 antibody (Becton-Dickinson), and then analysed in an EPICS flow 
cytometer (Coulter Electronics Ltd.). FITC-labelled goat anti-mouse IgM (Sigma) diluted 
1:100 was used with the Immunotech Vp2 antibody.
Statistics
'
The results are expressed as mean ± SEM: expression of Vp families in lesional skin and 
blood was expressed as a mean percentage of CD3+ T-lymphocytes. I used the Mann 
Whitney U-test to compare the T-cell counts in involved skin with those in uninvolved skin.
Wilcoxon's paired rank sum test.
■
3.3.3 Results
Expression of families in involved skin compared with PBLs
The number of CD3 positive lymphocytes was significantly increased in the upper dermis 
of involved skin (89 + 15 per high power field) compared with uninvolved skin (17 ± 3 per 
high power field) (P < 0.005). No CD3 positive lymphocytes were observed in the 
epidermis.
T lymphocytes expressing each Vp family in the dermis of involved skin and PBLs are 
represented as mean values ± standard error of the mean (SEM) for the group as a whole 
in Figure 3.3; Wilcoxon's paired rank sum test was used to analyse the data. Similar to 
other comparable studies [eg Menssen et al, 1995], for each individual patient, over­
representation of specific Vp receptors was considered significant if the number of T cells 
expressing the Vp receptor in the skin was at least double the number present in the 
PBLs. Thus, I found that 6 out of 10 patients had significant over-representation of Vp2 
(20.1 (mean) ± 4.5 (SEM) in skin; 5.6 (mean) ± 0.8 (SEM) in blood, P < 0.02); 8 out of 10 
patients had over-representation of Vp5.2/5.3 (4.9 ± 0.5 in skin; 2 ± 0.2 in blood, P < 0.01); 
and 7 out of 10 patients had over-representation of Vp5.3 (2.6 ± 0.6 in skin; 0.8 ±0.1 in 
blood, P < 0.05). Much larger numbers of ceils expressing TCR Vp2 were seen in 
comparison with TOR Vp5.2/5.3 and Vp5.3 (Figures 3.3 and 3.4).
Furthermore, 5 out of 10 patients demonstrated cytoplasmic staining with anti-Vp5.3 
antibody in involved but not uninvolved skin. These cells were scattered throughout the 
dermis and some were present in the vesicles. Two of these patients demonstrated similar 
staining with anti-Vp6.7 antibody. I did not count these cells when evaluating the sections 
because they did not exhibit the expected membrane staining as observed In other
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Boylston's antibody, I emipoyed a second V|32 antibody (Immunotech, Marseille, France). 
Similar results were obtained with the two antibodies for the PBLs although the 
Immunotech antibody stained approximately 1% less cells. However, I found that the 
Immunotech antibody gave high background staining on tissue sections which precluded 
enumeration of positively staining cells.
I was unable to interpret staining with the Vp antibodies in uninvolved skin as only small
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positively staining cells.
In an attempt to confirm the increased Vp2 expression in DH skin shown by A.
numbers of T cells were found.
3.3.4 Discussion
This study has shown over-representation of specific TCR Vp subsets, namely Vp2,
Vp5.2/5.3, Vp5.3 in DH lesional skin compared with blood. Large numbers of T-cells 
expressing Vp2 were observed in DH lesional skin (Figs. 3.3 and 3.4) compared with 
Vp5.2/5.3 and 5.3. Indeed, in one patient, 50% of the infiltrating T-cells expressed Vp2. My 
colleague, Dr Helen Lewis, has previously also shown preferential usage of TCR Vp2 in
by Leung et al [1995]. It could be hypothesised that T cells bearing TCR Vp2 "home in" to 
the skin in inflammatory dermatoses. However, Leung et al [1995], using the same Vp2 
antibody and a similar immunohistochemical technique as I did, demonstrated that
■ t;
expression of TCR Vp2 was not significantly increased in atopic eczema nor irritant 
dermatitis. Nor was TCR Vp2 expression found to be increased in lichen planus by PCR
psoriasis by immunohistochemistry [Lewis et al, 1993], a finding which has been confirmed
11
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[Dunn et al, 1993]. With regard to the TCR repertoire in normal skin, conflicting results 
have been obtained: one study demonstrated overexpression of TCR Vp2 in normal skin 
by PCR although this was found to be polyclonal by sequence analysis [Menssen et al,
1995]; another study demonstrated increased expression of TCR Vpl, Vp7, Vp14 and 
Vpi6 by PCR [Dunn et al, 1993]; and more recently, TCR Vp3 and Vp14 were shown to 
be significantly overexpressed in normal breast skin compared to PBLs [Ahangari et al,
1996].
I
DH is strongly associated with HLA A1, 88, DR3, DQ2 with over 95% of DH patients 
expressing the DQ2 antigen [Yunis Juan & Ahmed, 1991]. There is now good evidence 
from twin and family studies that the human TCR repertoire is primarily genetically 
determined [Loveridge etal, 1991]. Moreover, family studies support HLA class I and class 
II antigens as having a profound effect on the selection of T cells expressing particular Vp 
segments [Gulwani-Akolkar et al, 1991]. It has been proposed that HLA associations with 
disease may be explained by the effects of HLA antigens on determination of the TCR V 
segment frequencies, thereby biasing the individual toward the development of 
autoimmunity [Gulwani-Akolkar et al, 1991]. It is therefore perhaps not surprising that I 
found over representation of certain Vp families in DH lesional skin.
As over 90% of patients with DH have evidence of a GSE [Fry et al, 1972; Fry et al,
1974]. It is highly probable that the presence of GSE is necessary for the development 
skin lesions In these patients. It has previously been proposed that damage to the small 
bowel by gluten, exposes an antigenic determinant in the small intestine which is similar to 
a corresponding epitope in the skin [Baker et al, 1995]. T-cells recognising this antigen 
would therefore migrate from the small intestine to the skin. One candidate antigen could
,
be reticulin; patients with DH have anti-reticulin antibodies [Seah et al, 1971] and 
furthermore the titre of antibody correlates with the degree of intestinal damage [Hallstrom 
et al, 1985] (see discussion and hypothesis).
■
An intriguing finding from this study was the presence of cytoplasmic staining of Vp5.3 in 
5 out of 10 patients and of Vp6.7 in 2 out of 10 patients. It is known that specific 
recognition of antigen by T-cells is followed by internalisation of the T-cell receptor 
[Krangel, 1987]. It is possible, therefore, that these cells represented recently activated T- 
cells in which surface re-expression of the TCR had not yet occurred. Unfortunately, I have 
been unable to prove this.
To date, there have been no published studies on TCR Vp expression in the small 
intestine of patients with DH. Troncone et al [1995] have demonstrated over­
representation of TCR V(38 by immunohistochemistry in the lamina propria of untreated 
coeliac patients compared with controls. These findings, they concluded, supported the 
role of either an antigen or superantigen in the pathogenesis of coeliac disease. It remains 
to be shown whether there is over-expression of specific TCR Vp(s) in the small intestine 
of DH patients.
In summary, this study has shown bias of usage of TCR Vp receptors which implicates 
the involvement of an antigen or superantigen in the pathogenesis of DH skin lesions.
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FIGURE 3.3: Expression of Vp families in the lesional skin and blood of 10 
patients with dermatitis herpetiformis, expressed as a mean percentage of CD3+ T- 
iymphocytes. ^  indicates Vp families significantly elevated in the skin compared 
with peripheral blood lymphocytes using Wilcoxon's paired rank sum test (P < 
0.05).
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FIGURE 3.4: immunoperoxidase staining of the upper dermis in lesional 
dermatitis herpetiformis skin from a representative patient for (a) CD3 and (b) TCR 
Vp2 expression (x400).
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CHAPTER 3 
LABORATORY STUDIES
4. CYTOKINES IN THE SMALL INTESTINE OF DH PATIENTS 
USING IMMUNOHISTOCHEMISTRY AND THE POLYMERASE 
CHAIN REACTION
3.4.1 Introduction
The mechanisms whereby gluten causes damage to the small Intestine in CD and DH is 
unknown. T cell mediated mechanisms have been implicated in the pathogenesis because 
of the similarity between the histological features of GSE and graft versus host disease 
(GvHD) [Neild, 1981] and the characteristic finding of elevated numbers of intra-epithellal 
lymphocytes (lELs) in the small intestine of patients with CD and DH which decrease 
during a gluten free diet (GFD). Furthermore, normal foetal small bowel, exposed in vitro 
to T cell activators, develops villous atrophy and crypt hyperplasia [MacDonald & Spencer, 
1988]. These changes in small intestinal morphology in GSE may be induced by gluten 
specific T cells via the production of cytokines; antibodies to interferon-y (IFN-y) abolished 
the development of small intestinal GvHD [Mowat, 1989]. Previous studies have examined 
the T cell cytokine IFN-y in CD with conflicting results [Al-Dawoud et al, 1992; Kontakou et 
al, 1994]: no similar studies have been published on DH small intestine to date.
The aim of this study was, therefore, to examine the expression of the cytokine IFN-y 
using RT-PCR to detect cytokine specific mRNA and immunostaining to enumerate 
cytokine positive cells in DH gut versus normal gut mucosa. In addition, mRNA and protein 
for the T cell growth factors, interleukin-2 (IL-2) and interieukin-4 (IL-4) were studied.
I l l
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3.4.2 Patients and methods
Patients and biopsy specimens
Ethical approval was given by St Mary’s Hospital Local Ethics Committee; patient consent 
was obtained prior to biopsies being taken. Peroral biopsies were taken from the second
■I
part of the duodenum at endoscopy from patients with DH taking a normal diet (n=6, mean 
age” 57 years, range 51-68) and from controls (n=6, mean age=46 years, range=26-71) 
who were being investigated for abdominal pain or dyspepsia. Small intestinal biopsies 
from the controls were all shown to be normal. Biopsies from the DH patients all 
demonstrated villous atrophy (3 patients had severe villous atrophy and 3 partial villous 
atrophy), crypt cell hyperplasia, increased Intra-epithelial lymphocyte counts and reduced 
villous height/crypt depth ratios compared with the controls. I was present whilst patients 
and controls underwent endoscopy so as to collect the specimens which I snap froze in 
liquid nitrogen. I used a dissecting microscope to orientate specimens, which I planned to 
use for immunostaining, on liver with the villi uppermost before snap freezing; and, 
immediately prior to cutting, I embedded them in OCT (Tissue Tek®); I then cut 5pm 
sections using a cryostat (Slee, London).
RNA extraction and cDNA synthesis
Total RNA was extracted from homogenised whole gut using TRIzol reagent, a mixture of 
phenol and guanidine isothiocyanate, according to manufacturers instructions (Gibco BRL, 
Paisley, Scotland). cDNA was then synthesized by incubation of 4 pg RNA with 200U 
MMLV reverse transcriptase (Gibco BRL), 20 ng oligo(dT)i2-i8 primer (Pharmacia Botech, 
St Albans, Herts) and 10 mM of each 4 dNTP (Pharmacia) in the presence of 0.1 M DTT 
(Gibco BRL) in a 20 pi reaction volume for 1 hr at 42°C. The reaction was stopped by 
incubating at 95°C for 3 mins, followed by cooling on ice.
;1
PCR
0.5 [i\ cDNA was amplified in each PCR reaction in a 25^1 volume. The final concentration 
of the reaction mixture was 0.625U Taq polymerase (Gibco BRL), 0.2mM each dNTP and 
75 ng of each 5' and 3' cytokine-specific or p-actin primer (Oswel DNA service, Edinburgh) 
in PCR buffer containing 1mM MgClg and 0.05% W1 detergent. The reaction mixture was 
overlaid with mineral oil and amplified by 30 (IL-4) or 35 (IL-2, IFN-y, p-actin) cycles in a
I
DNA thermocycler (Perkin-Elmer, Applied Biosystems, Warrington, Cheshire). Each cycle 
consisted of dénaturation at 94°C for 1 min, annealing at 55°C for 1 min (IL-2, IFN-y, p- 
actin) or 65°C for 2 mins (IL-4) and extension at 72'^C for 1 min. The temperature was 
maintained at 72'^C for 5 mins after the final cycle to allow completion of synthesis of 
amplified products.
The PCR products were separated from the primers by electrophoresis on a 1.5% 
agarose gel containing 10 pg/ml ethidium bromide, and visualised under UV light. They 
were then transferred onto Hybond-N nylon membrane (Amersham, Bucks, UK), 
hybridised at 55°C overnight with ^^P-labelled cytokine-specific probes and visualised by 
autoradiography. Densitometer readings of the cytokine-specific bands were normalised to 
those of p-actin before statistical analysis. One of the control cDNA samples did not give a 
signal for p-actin and was not, therefore, studied further.
The sequence of the primer pairs and probes specific for IL-2, IFN-y and p-actin used in 
the study were taken from Yamamura et al [1992].
The RNA extraction, cDNA synthesis and PCR were performed by Mr Senur Bokth 
(Laboratory Assistant) under the supervision of Dr Barbara Baker.
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staining technique
I used the avidin-biotin peroxidase technique, as described in section 3.1.2, and 
monoclonal antibodies against CDS (Becton Dickinson, Oxford, UK), IFN-y (Sera-Lab, 
Sussex, UK), IL-2 and IL-4 (Genzyme, Kent, UK). I initially incubated the sections with the 
cytokine antibodies diluted 1:10 at 4*^0 overnight followed by incubation at room 
temperature with biotinylated horse-anti-mouse secondary antibodies.
Negative controls consisted of omission of the primary antibody or its substitution with 
mouse IgG (Vector Laboratories, Peterborough, UK) used at a dilution of 1:10. For positive 
controls, I stained tuberculin-purified protein derivative-induced delayed hypersensitivity 
type reactions biopsied at 48 hours: these showed the presence of dermal cells which 
stained positively with antibodies to IFN-y, IL-2 and IL-4.
Enumeration of positively stained cells
I counted the number of intra-epithelial lymphocytes expressing CDS per 1000 epithelial 
cells. For quantification of positively stained cells in the lamina propria I used an eye piece 
graticule under x400 magnification. The eye piece graticule was divided into 100 x Imm^ 
squares: I counted at least 500 hundred of these squares in consecutive areas in 2-4 
sections (within and below the villi going into the deeper lamina propria to the level of the 
crypts) and I expressed the results as the mean number of positive cells per unit area ie 
SOOmm^ .
All the counting was performed by myself but in order to confirm reproducibility, a 
sample of sections chosen at random were counted by my colleague Dr Barbara Baker.
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Statistical analysis
I used the Mann-Whitney U test to compare the immunostaining and PCR densitometer 
values obtained from the DH and normal groups.
3.4.3 Results
Control mucosa
Expression of IFN-y-specific mRNA was readily detected in all the normal gut biopsies, but 
levels were variable (Figure 3.5). In addition, a mean of 69 (12% of CD3+) cells in the 
lamina propria were shown to be IFN-y-positive by immunostaining (Table 3.5). In contrast, 
IL-2 mRNA was barely detectable in 3 of the normal biopsies but strongly expressed in the 
other two although only one of the replicates gave a positive result in each case (Figure 
3.5). This was associated with a lower frequency of IL-2 compared to IFN-y-positive cells 
in the lamina propria by Immunostaining (Table 3.5). However, unlike IL-2 and IFN-y, the 
PCR and immunostaining findings for IL-4 did not correlate. Thus a mean of 117 lamina 
propria cells stained for IL-4 but IL-4 mRNA was undetectable In all but one of the normal 
gut biopsies (Table 3.5, Figure 3.5). Many of the cells expressing IL-4 protein were 
probably mast cells with the cytokine stored In their cytoplasmic granules. The lack of 
mRNA for IL-4 would suggest that these cells were not actively synthesising IL-4 at the 
time of the small intestinal biopsy.
Dermatitis herpetiformis mucosa
Strong expression of IFN-y-, and to a lesser extent, IL-2-specific mRNA was observed in 
all of the DH guts with some variability of the latter (Figure 3.5). These levels were not, 
however, significantly raised compared to the normal gut biopsies, Immunostaining 
demonstrated comparable numbers of cells expressing IFN-y and IL-2 in individual
3.4.4 Discussion
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patients (Table 3.5, Figure 3.6). Although the absolute number and proportion of IL-2- 
positive cells were increased in DH versus control mucosa, these differences did not reach 
statistical significance (p=0.07). Furthermore, the number of IFN-y- and IL-4-positive cells 
were similar in the two groups. IL-4 mRNA was, however, only weakly expressed in 2 out 
of the 6 DH gut biopsies (Figure 3.5).
Cells expressing IFN-y and IL-2 were morphologically similar to T cells. Although some 
cells expressing IL-4 were also T cell-like, many which contained granules in the 
cytoplasm were probably mast cells (Figure 3.6). IL-4 positive cells were not therefore 
expressed as a frequency of CD3 positive T cells.
In the epithelium, cells staining positive for IFN-y and IL-4 were either infrequently 
present or absent in DH and normal guts. Staining of epithelial cells by the anti-IL-2 (DH 
and normal) and anti-IFN-y (DH) antibodies made evaluation of positively stained intra- 
epithelial cells inaccurate.
I?This study has shown no significant differences in mRNA or protein for IFN-y, IL-2 or IL-4, 
in the small intestine of patients with DH compared with control biopsies. However,
:■
approximately twice as many cells expressing IL-2 protein were present in the DH guts 
compared with controls but this did not quite reach statistical significance (p=0.07).
No increase in the absolute number of T cells expressing protein for IFN-y was detected 
in the lamina propria of DH patients when compared with controls which is in agreement 
with a previous immunohistochemical study of IFN-y in CD [Al-Dawoud et al, 1992].
However, this same study [Al-Dawoud et al, 1992] found a decrease in the proportion of 
cells expressing IFN-y in CD when they expressed these cells as a percentage of the total 
number of cells expressing CD45 which would have included T cells, B cells, monocytes, 
macrophages and granulocytes. In contrast, another study of CD patients found a 
significant increase in the number of cells expressing mRNA for IFN-y in the lamina propria 
when compared with that of controls [Kontakou et al, 1994]. However, staining for IFN-y by 
immunohistochemistry was not performed and it Is possible that the IFN-y mRNA was not 
translated into protein.
IFN-y has been Implicated in the pathogenesis of the gut changes seen in CD because 
in a mouse model of GvHD, in which the morphological changes are similar to GSE [Neild, 
1981], antibodies to IFN-y abolished the development of intestinal GvHD [Mowat, 1989]. 
IFN-y may have a direct effect on intestinal tissues: It has been shown to have the ability to 
modify the barrier function of the intestinal epithelial cells resulting in altered permeability 
[Adams et al, 1993; Madara & Stafford, 1989] and can influence ion and electrolyte 
secretion [Holmgren et al, 1989]. Alternatively, the changes may be due to the ability of 
IFN-y to activate other immune effector cells which in turn may have direct effects on the 
tissues or act via production of further inflammatory mediators. It is possible that the small 
intestinal changes observed in DH and CD may be due to altered receptors for IFN-y or 
due to an abnormal end organ response to this cytokine, but it does not appear to be due 
to an increase in the quantity of this cytokine.
Other cytokines have been implicated in the aetiology of the morphological changes of 
GSE. A recent study in CD reported an increase in the total number of macrophages in the 
lamina propria expressing the cytokines IL-6 and tumour necrosis factor a [Przemioslo et
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been shown to possess receptors to IL-2 and IFN-y which are functional [Madara & 
Stafford, 1989; CiaccI et al, 1993]. The staining of epithelial cells with IL-2 and IFN^
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al, 1994] and the authors concluded that these cytokines may be involved in the 
pathogenesis of GSE. However, it is more likely that these cytokines are part of the 
inflammatory process and not the causal agents. Another study found increased numbers 
of cells expressing IL-4 by immunohistochemistry in DH small intestinal biopsies and it was 
proposed that TH2 T helper cells were involved in the aetiology of the small intestinal 
changes [Hall et ai, 1994]. My study does not support this hypothesis. Indeed, I found a
poor correlation between expression of mRNA and protein for IL-4.
I
Strong epithelial staining with antibody to IL-2 was observed in both control and DH
patients and to a lesser extent with IFN-y antibody in the DH patients. This made 
assessment of positively staining intra-epithelial lymphocytes difficult. Epithelial cells have
antibodies could have been due to binding of these cytokines, secreted by Intraepithélial or 
subepitheliai lymphocytes, to receptors.
In conclusion, if cytokines are responsible for producing the morphological changes 
observed in the small intestine of DH patients, it is likely that a complex interaction of 
several cytokines Is involved. Further work is required to elucidate the involvement of 
cytokines and thus advance our knowledge of the pathogenic mechanisms involved in this 
disorder.
I
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FIGURE 3.5: Cytokine-specific mRNA in DH and normai gut mucosa. After 
eiectrophoresis, PCR products for iFN^, iL-2, iL-4 and p actin were probed with a 
radioiabeiied oiigonucleotide internai for each primer pair. From the ieft hand side, 
dupiicate sampies were run for the six DH patients and the six controls. CON = PHA- 
stimuiated PBL controi.
D H . NORMAL CON
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FIGURE 3.6: immunoperoxidase staining of dermatitis herpetiformis lamina 
propria taken from a patient with partial villous atrophy demonstrating cells 
staining positively for (a) IFN-^, (b) IL-2 and (c) IL-4 (x400). The arrowheads indicate 
some examples of positively staining ceils.
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TABLE 3.5: Counts of intraepithélial and lamina propria CD3 positive T cells, and cells expressing cytokines 
IFN-y, IL-2 and IL-4 in lamina propria
lEL** IFNY IL-2^ ^ IL-4^
Controls /? = 6 82 ±12 535 ± 78 69 ±16 45 ± 14 117 ± 14
Range (30- 105) (248-782) (22-135) (25-113) (82-149)
% (12% ±1) (8%±1)
DH guts n = 6 413 ±53* 585 ± 61 79 ±8 81 ±9 125 ±12
Range (192-576) (357 -  744) (53-113) (47-107) (86-154)
% (15% ±4) (15% ±3)
* P < 0.005, Mann Whitney U test
** T cells counted per 1000 epithelial cells
*** T cells counted per unit area of lamina propria
Cells positive for IFN-y expressed per unit area 
Cells positive for IL-2 expressed per unit area 
Cells positive for IL-4 expressed per unit area 
n number of patients
% positively staining cells expressed as a percentage of CDS positive cells
CHAPTER FOUR
DISCUSSION AND HYPOTHESIS
I
124
CHAPTER 4 
DISCUSSION AND HYPOTHESIS
4.1 Discussion
The term dermatitis herpetiformis encompasses both the skin and the small Intestinal 
changes observed in this condition. The rash and the enteropathy of DH are both triggered 
by the storage proteins found in the cereals wheat, barley and rye. Oats have also been 
incriminated but their involvement in the aetiology of dermatitis herpetiformis, and coeliac 
disease, is controversial. Indeed, a recent study suggested that oats were not toxic in CD 
[Janatuinen et al, 1995] and my own group demonstrated that moderate amounts of pure 
oats could be added to the diets of DH patients without deleterious effects to the skin or 
intestine [Hardman et al, 1997]. Cereals contain many storage proteins but it is the 
alcohoi-soluble fractions, known as proiamins, that are responsible for triggering the rash 
and enteropathy of DH. In wheat, the proiamins are known as gliadins. Although we know 
that ingestion of giiadin, in susceptible individuals, leads to the development of DH, the 
mechanisms involved remain elusive.
In addition to involvement of giiadin as the trigger, pathogenic mechanisms of DH would 
have to take into account the additional clues provided by research since the late 1960s 
including the following findings: the presence of IgA in the dermal papillae of the skin; 
genetic susceptibility to developing DH; the presence of circulating ARA and AEA; and the 
knowledge that there are activated T cells in the skin.
The skin and small intestinal changes of DH appear to be inextricably linked, and in my
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view, It is very likely that the development of the rash is dependent on the presence of the 
enteropathy. Therefore, it seems probable that common pathogenic mechanisms exist for 
both organs. With regard to CD, two main theories prevail in the literature and these are T
:
cell mediated mechanisms and autoimmune processes. Let us consider each of these in 
turn for CD.
Possible mechanisms whereby giiadin induces the enteropathy of coeliac disease 
i) GSE is due to T cell mediated mechanisms
There is much circumstantial evidence to support the hypothesis that the small intestinal 
changes of coeliac disease are mediated by T cell mechanisms.
In untreated coeliac disease, the number of T cells within the epithelium is increased. 
The vast majority of lELs are CD3+ T cells and 70-90% express CD8+ with many 
expressing CD45RO (memory ceils) in addition. Most lELs express the conventional T cell 
receptor a/p; oligoctonality of these cells has been demonstrated in normal small intestine 
indicating that these cells are specific for a limited number of antigens [Balk et al, 1991; 
Blumberg et al, 1993]. A minority of lELs express the y/0 T cell receptor. The function of T 
cells expressing the y/0 TCR is unknown but their numbers are increased in the epithelium 
of CD (and DH) [Spencer et al, 1989; Halstensen et al, 1989; Savllahti et al, 1990; 
SavilahtI et al, 1992]. In contrast with T cells expressing the a/p TCR, lELs expressing the 
y/S TCR remain elevated after withdrawal of gluten from the diet [Savllahti et al, 1992]. 
Furthermore, the presence of elevated numbers of lELs expressing the y/6 TCR, in 
otherwise normal individuals, is a marker for those with latent CD or DH [Màki et a/,1991; 
Savllahti et al, 1992] or for those with a genetic susceptibility to develop CD [ Holm et al,
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1992].
Increased numbers of T lymphocytes are also observed In the lamina propria of 
untreated coeliac disease. These are predominantly CD4+ CD45RO+ indicating that these 
are antigen-primed or memory cells. The a/(3 TCR is the predominant TCR and 
upregulation of expression of CD25 (interleukin 2 receptor) has been shown to occur 
[Halstensen & Brandtzaeg, 1993]. Polyclonal T cell lines and T cell clones recognising 
giiadin have been established from coeliac mucosa [Lundin et al, 1993]. These T cells 
were CD4+ and recognised giiadin when presented by antigen presenting cells expressing 
the CD-associated DQ (A1*0501, B1*0201) heterodimer. It has been proposed that in vivo 
these T cells interact with antigen and produce cytokines which have damaging effects on 
the mucosa.
Other studies support the involvement of cytokines produced by activated T cells. 
Addition of the T cell activators pokeweed mitogen and anti-CD3 to organ cultures of foetal 
small bowel resulted in an increased proliferation of epithelial cells, crypt hyperplasia and 
villous atrophy: IL-2 and y-lFN were detected in supernatants of damaged explants 
[MacDonald & Spencer, 1988]. Furthermore, antibodies to y-IFN abolished the 
development of intestinal graft versus host disease [Mowat, 1989]. These studies would 
tend to support involvement of TH1 T cells ie those which produce IL-2 and y-IFN. y-IFN 
has been implicated in the pathogenesis of coeliac disease because of the evidence 
outlined above and also because increased levels of y-IFN were demonstrated in CD small 
intestinal mucosa compared with normal mucosa [Kontakou et al, 1994]. However, if this 
hypothesis is correct, then other factors must be operating as addition of y-IFN to organ 
cultures did not result in villous atrophy nor crypt hyperplasia [MacDonald & Spencer,
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1988]. My own work, outlined in Chapter 3.4, did not show a significant increase in y-IFN in 
DH small intestine compared with controls and my findings were in agreement with others 
[Al-Dawoud etal, 1992].
Recent work has further contributed towards our understanding of the pathogenesis of 
CD. The main target antigen for AEA has been identified as tissue transglutaminase (tlG ) 
[Dieterich et al, 1997]. TTG is a calcium dependent enzyme which catalyses the cross- 
linking of proteins resulting in the formation of s-(y-glutamyl)-lysine bonds. It is normally 
localised within the cytoplasm but can be released during wounding and is thought to 
stabilise the extra-cellular matrix in granulation tissue. Dieterich and his colleagues were 
able to demonstrate that giiadin was an excellent substrate for tTG and was quantitatively 
cross-linked by it [Dieterich et ai, 1997]. Subsequently, an elegant set of experiments 
showed that tTG enhanced the recognition of giiadin by T cells derived from the small 
intestine by ordered and specific deamidation of giiadin resulting in an epitope that bound 
efficiently to HLA-DQ2 on antigen presenting cells [Molberg et al, 1998]. This effect was 
limited to T cells derived from the small intestine as it could not be replicated using 
peripheral blood [Molberg etal, 1998].
Despite the plethora of evidence supporting T cell mediated mechanisms in the 
development of the enteropathy of CD, it is not known if T cell activity is indeed the initial 
event or secondary to other mechanisms.
n) GSE is due to autoimmune mechanisms
There is substantial evidence to suggest that CD may be an autoimmune disease. All the 
elements essential for an autoimmune process are present in CD: the trigger (giiadin),
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susceptibility MHC class II genes and the autoantigen.
CD is strongly associated with the HLA molecules B8, DR3, DQ2 and DQ8 encoded by 
the major histocompatibility complex. Approximately 95% of CD patients carry the 
heterodimer DQA1*0501 DQB1*0201 (DQ2) in cis or trans [Sollid et al, 1989; Hall et al, 
1991]; most of the remaining CD patients instead carry genes encoding the DQ A1*03 
DQB*0302 heterodimer also known as DQ8 [Spurkland etal, 1992; Mantovani etal, 1993; 
Tighe etal, 1993; Sollid etal, 1993]. The HLA class II molecules DQ2 and DQ8 on antigen 
presenting cells could present self-peptides.
Patients with CD produce antibodies directed against reticulin (ARA) and endomysium 
(AEA) and these antibodies have a high sensitivity and specificity for CD. Furthermore, the 
levels of these antibodies diminish and eventually disappear when giiadin has been 
withdrawn from the diet. Giiadin has been shown to drive the production of AEA in organ 
cultures of small intestine [Picarelli et al, 1996]. These findings raise the possibility that 
ARA and AEA, or the antigen recognised, are involved directly in the pathogenesis of CD, 
ARA and AEA have been shown to be directed against fibroblast derived extra-ceilular 
matrix proteins termed coeliac disease autoantigen proteins [Martinnen & Maki, 1993;
Maki et al, 1991; Maki, 1995]. Autoantibodies recognise antigenic determinants or 
epitopes which are highly conserved in evolution and it has been demonstrated that T cells 
specific for these cryptic epitopes may escape thymic education and become activated 
and autoagressive when the epitopes are presented in high concentrations [Quarantino et 
al, 1996]. These cryptic epitopes may become visible to the immune system by damage to 
the intestinal mucosa caused by giiadin and/or binding of giiadin to self antigens.
. a
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The recent discovery that the predominant, if not sole, target antigen for AEA is tTG 
and that the preferred substrate for tTG is giiadin, [Dieterich et al, 1997] has given further 
credence to the auto-immune hypothesis of CD. Dieterich and his coworkers hypothesised 
that damage to the small intestine, perhaps by toxic fractions of giiadin, triggers the 
release of tTG from its normally intracytosolic compartment; this in turn leads to 
subsequent cross-linking of giiadin resulting in gliadin-gliadin and gliadin-tTG complexes 
thus creating antigenic neotopes; these neotopes could then initiate an immune response 
directed against giiadin and tTG in genetically susceptible individuals [Dieterich et al, 
1997].
Thus presentation of antigenic neoepitopes by antigen presenting cells expressing 
DQA1*0501 DQB1*0201 to the T cells, primes and triggers T cells - continued ingestion of 
the giiadin sustains the autoimmune response. However, in contrast with other 
autoimmune diseases, the immune processes cease and the pathological changes 
reverse once the trigger, giiadin, has been withdrawn.
Let us now consider the above hypotheses in relation to the pathogenesis of DH skin 
lesions.
i) T cell mediated mechanisms
Like CD, dietary giiadin is the trigger for the rash and intestinal changes observed in DH. I 
have been able to show unequivocally that the rash of DH resolves following withdrawal of 
gluten from the diet although it takes many months for the skin to heal completely. 
Eventually, so long as patients adhere to a strict GFD, the amount of IgA within the skin 
declines and eventually disappears.
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My work has shown the presence of large numbers of activated CD4+ T cells, many of 
which were memory cells, in the dermis of DH lesional skin. Their close apposition with 
Langerhans’ cells would suggest that a cell mediated immune response was taking place. 
Furthermore, I was able to demonstrate restricted I  cell Vp gene expression suggesting 
that these T cells were recognising a limited number of antigens. However, intradermal
injection of Frazer’s fraction III failed to reproduce the skin lesions of DH clinically nor did I 
observe an influx of T cells histologically. In addition, my colleague Dr Baker has been 
unable to isolate T cells recognising giiadin as an antigen from DH lesional skin [Baker et 
al, 1995]. Previous studies have failed to identify the presence of giiadin in the skin of DH 
patients [Eterman et al, 1977; Pehamberger et al, 1979]. Therefore, although my work 
would support the involvement of T cell mediated mechanisms in the pathogenesis of DH 
skin lesions, it seems likely that the T cells are recognising an antigen other than giiadin.
ii) Autoimmune hypothesis
The elements essential for an autoimmune process are also present in DH: the trigger 
(giiadin), susceptibility MHC class II genes and the autoantigen. Let us consider the 
possible autoantigen.
Levels of ARA and AEA decline and eventually disappear in DH patients who have
excluded gluten from their diets. The high specificity of these antibodies for DH suggests 
that they, or their antigen, may be important In the pathogenesis of the skin lesions. In 
Chapter 3.2, I proposed the possibility that the activated T cells in DH lesional skin could 
be reacting to a component of the skin. Previous work by Unsworth and his colleagues has 
shown that reticulin is present in human skin and that it is most abundant in the dermal 
papillae and immediately below the basement membrane zone [Unsworth et al, 1981]. The '
a
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As mentioned above, in respect to CD , tTG has been identified as being the target 
antigen for AEA and this could be relevant to the pathogenesis of the rash of DH. In the 
skin, tTG is found along the dermo-epidermal junction, in the micro-fibrillar apparatus of 
the papillary dermis and surrounding capillaries and in differentiating epidermis -  it
sites of abundant reticulin correspond to the localisation of IgA in the skin and this gives 
support to the proposal made by Seah and his coworkers that that the IgA may in fact be 
binding to reticulin fibres [Seah etal, 1972].
appears to play an important role in cross-linking the papillary dermis and the dermo-
iepidermal junction [Raghunath et al, 1996]. Thus, with the exception of the dermal 
capillaries and differentiating epidermis, tTG Is present at the same sites as IgA in the skin 
of DH patients.
Therefore, there would appear to be two potential autoantigens in DH: reticulin and tTG. 
In susceptible individuals, giiadin could damage reticulin in the small intestine or it could 
crosslink with tTG to form neoepitopes. This would lead to priming and triggering of 
relevant T cells some of which would enter into the general circulation and eventually find 
their way to the skin where they would interact with antigen, produce cytokines which 
would initiate the cascade of events leading to production of DH skin lesions.
4.2 Hypothesis
Taking existing evidence into account, I favour the following hypothesis.
Ingestion of toxic fractions of giiadin, in genetically susceptible individuals, leads to 
damage of the small intestine. This results in exposure of self antigens, which are normally
I
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hidden from the immune system, and renders them immunogenic by damaging them or by 
adhering to them. A possible candidate antigen could be reticulin because ARA Is a 
feature of DH and has a high specificity in the diagnosis of DH. Furthermore, like patients 
with CD, DH patients are at risk of developing splenic atrophy and a major component of 
the spleen is reticulin. In light of recent work, a second possible antigen could be tTG 
which would be released following giiadin induced damage: tTG-gliadin and gliadin-gliadin 
complexes would form leading to the production of neoepitopes. The development of 
neoepitopes in turn leads to eventual activation and proliferation of autoreactive T cells.
These autoreactive T cells then enter the general circulation and some eventually find 
their way to the skin where they react with reticulin or with tTG. This results in the 
production of cytokines by these T cells and this in turn leads to the production of IL-8 by 
the epidermal cells and GM-CSF by dendritic cells at the basement membrane [Graeber et 
al, 1993]. Neutrophils enter the dermis slightly later than the T cells; the presence of IL-8 
on the epidermal cells causes them to migrate towards the epidermis. IgA, present in the 
tips of the papillae, attaches to receptors on the neutrophils causing activation of the 
neutrophils which then produce cytokines and inflammatory mediators eventually leading 
to destruction and damage in the region of the basement membrane resulting in 
subepidermal blistering.
Continued ingestion of giiadin leads to continued production of a population of T cells 
primed against reticulin or tTG whilst withdrawal of giiadin from the diet results in a gradual 
decline in the numbers of primed T cells. This could explain why it takes so long for the 
rash to clear once exposure to giiadin has ceased and why re-ingestion leads to rapid 
activation and proliferation of the T cells accounting for recurrence of the rash within a few
133
weeks.
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4.3 Final discussion
Genetic factors appear to be important in the aetiology of DH and CD as these conditions 
tend to cluster in families and my work has shown that many so-called "unaffected” family 
members may in fact have silent or latent CD (Chapter 2.3). Although there is a strong 
association with the HLA molecules DQA1*0501 DQB1*0201 and DQ A1*03 DQB*0302, 
other non HLA factors must be operating as not all individuals with these HLA types 
develop CD or DH. A number of possible gene linkage sites has been reported [Zhong et 
al, 1996; Houlston et al, 1997; Breco et al, 1998]. One of the pitfalls in looking for gene 
linkage for CD and DH is that it is insufficient to exclude CD in "normal" individuals on the 
basis of serology alone -  my work has shown that CD can only be absolutely excluded by 
small intestinal biopsy. The discovery of the candidate gene(s) for CD and DH should lead 
to a better understanding of the pathogenesis of these conditions and should explain why 
only a small percentage of patients with CD develop the rash of DH.
Finally, my work has confirmed the efficacy of a GFD in the treatment of DH, not only 
because it allows healing of the skin and small intestine to occur, but also because it 
reduces the risk of these patients developing lymphoma.
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